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Abbreviations 
 
APS ammonium persulfate 
AR retinoic acid 
BSA albumin from bovine serum 
BTB bric-à-brac, tramtrack and broad 
CD circular dichroism  
CNS central nervous system 
CTD C-terminal domain 
Cul cullin 
dam DNA adenine methylase  
Dhh Desert Hedgehog 
DMEM Dulbecco's Modified Eagle Medium 
dNTP deoxy nucleotide tri-phosphate 
DTT dithiothreitol 
ECL enhanced chemi-luminescence  
EDTA ethylene-diamino-tetraacetic acid 
ESI electron spry ionization source 
FBS foetal bovine serum 
FPLC Fast protein liquid chromatography 
GCP Granule cell progenitors 
GST Glutathione S-Transferase 
GTE Glucose-Tris-EDTA 
Hh Hedgehog 
HPLC high performance liquid chromatography 
HSQC heteronuclear single quantum coherence 
Kd dissociation constant 
IGL internal germinal layer 
Ihh Indian Hedgehog 
IPTG isopropyl-beta-D-thiogalactopyranoside 
KCTD Potassium Channel Tetramerization Domain 
LB Luria-Bertani Broth  
LC-MS liquid chromatography mass spectrometry 
MB medulloblastoma 
MBP Maltose Binding Protein 
MCS multi cloning site 
ms millisecond 
MWCO molecular weight cut off 
Ni-NTA nickel-nitrilotriacetic acid 
NMR Nuclear Magnetic Resonance 
NOESY Nuclear Overhauser Effect Spectroscopy   
NTD N-terminal domain 
orf open reading frame 
PBS phosphate buffer saline 
PCR polymerase chain reaction 
POZ poxvirus zinc finger 
PVDF polyvinylidene fluoride 
REN retinoic acid, epithelial growth factor, nerve growth factor 
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SCF Skp1–Cullin–F-box protein 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
Shh Sonic Hedgehog 
STD saturation transfer difference 
TAE Tris acetate EDTA 
TE Tris/HCl-EDTA 
TEMED N,N,N’,N’-tetramethyl ethylene diamine 
TEV tobacco etch virus 
Tris Tris (hidroxy methyl) amino methane 
TrxA thioredoxin A 
Ub ubiquitin 
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Summary 
 
Hedgehog (Hh) signaling is suggested to be a major oncogenic pathway in 
medulloblastoma, which arises from aberrant development of cerebellar granule 
progenitors. Hh signaling is regulated by ubiquitin ligases E3, that process the 
downstream transcription factors Gli via dual Cullin-based ubiquitin-dependent 
pathways. Interestingly, Cullin3 has been shown to require proteins containing BTB 
(Broad Complex, Tramtrack and Bric a Brac) domain to target substrates. Recently a 
human BTB protein has been identified, RENKCTD11, which displays allelic deletion as 
well as significantly, reduced expression in medulloblastoma. Data in vitro have 
suggested that RENKCTD11 binds Cullin3 and indirectly promotes the degradation of 
Gli1 thus inhibiting the transactivation of the Hedgehog target genes. Although the 
available literature data clearly show the role of RENKCTD11 as tumour suppressor, its 
biochemical properties remain to be defined. In this context we have undertaken a 
structural and functional study on RENKCTD11 protein. Human genomic region coding 
for RENKCTD11 has been amplified by PCR, cloned and over-expressed in Escherichia 
coli in soluble form, as a fusion product with Maltose Binding Protein (MBP). The 
protein has been purified to homogeneity by only one purification step utilizing the 
presence of His-tag. Size exclusion chromatography allowed to structurally 
characterize RENKCTD11 as an homotetramer in agreement with in silico analysis. The 
TEV-digested protein sample was extremely unstable. The alignment of RENKCTD11 
sequence with sequence databases shows that a region of almost one hundred 
residues presents a significant degree of similarity with the POZ/BTB domain of 
potassium (kv4) channel. Bioinformatic analyses have allowed to identify the exact 
extension of POZ/BTB domain of RENKCTD11. It has been cloned, expressed as a 
fusion product with Thioredoxin-A (TrxA), purified in soluble form as a tetramer and 
characterized by mass spectroscopy, circular dichroism and light scattering. The 
homogeneous protein has been used for crystallization tests. Site-directed 
mutagenesis has been used to validate the ionic interactions responsible of the 
POZ/BTB domain tetrameric form. The mutant D69A/R74A/N78A/R81A resulted 
strongly unstable. These data confirmed the key role of these residues in the 
stabilization of the tetrameric form of the protein. The experimental evidence that 
POZ/BTB of RENKCTD11 forms a stable tetramer in solution prompted us to check the 
possibility to generate by homology modelling a RENKCTD11 POZ/BTB-Cul3 complex 
with a 4:4 stoichiometry. A peptide corresponding to residues 49-68 (NH2-
NSGLSFEELYRNAYTMVLHK-COOH) of Cul3 has been individuated as responsible 
of interaction with the domain POZ/BTB of RENKCTD11. The peptide binds POZ/BTB 
of RENKCTD11 with an apparent affinity constant of 0.8 μM. Then, we tried to 
investigate whether the same region of Cul3 was responsible for interaction with 
POZ/BTB domains of other KCTD proteins. It was chosen as the starting point 
KCTD5, a cytosolic protein whose crystal structure has been recently deposited. The 
POZ/BTB domain of KCTD5 with five aminoacids added at N-terminus (region 40-
151) was expressed in E. coli and obtained in large amount. The results obtained by 
ELISA show that this POZ/BTB domain binds the helix 49-68 of Cul3 with an affinity 
similar to that of the BTB/POZ of RENKCTD11. Finally we present a mechanism of 
function of RENKCTD11 applicable to other members of KCTD family that, interacting 
with the ubiquitin-ligase-E3, regulate some of the most important cellular metabolic 
pathways by their POZ/BTB domains. 
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Riassunto 
 
Questa tesi di dottorato si inserisce in un più ampio progetto volto alla definizione 
delle basi molecolari del ruolo biologico dell’oncosoppressore del medulloblastoma 
RENKCTD11, una proteina presente nel pathway Sonic-Hedgehog (Shh). Le Hedgehog 
sono glicoproteine coinvolte in processi metabolici che regolano lo sviluppo e il 
differenziamento cellulare. Sonic Hedgehog in particolare regola lo sviluppo del 
sistema nervoso centrale e il differenziamento delle cellule progenitrici del cervelletto 
[Ruiz i Altaba, et al. 2002], [Palma V., et al. 2005]. La deregolazione di tale pathway 
determina la formazione di molti tumori del cervello. Tra questi vi è il 
medulloblastoma, che è causato da diverse alterazioni genetiche ed epigenetiche 
che influenzano lo sviluppo delle cellule progenitrici dei granuli del cervelletto (GPC) 
la cui proliferazione è regolata dalla proteina Sonic Hedgehog, secreta dalle cellule 
del Purkinjie. In seguito all’interruzione del segnale Shh le GPCs smettono di 
proliferare ed iniziano a differenziarsi. La mancata interruzione del segnale Shh si 
ritiene essere la principale causa dell’insorgenza del tumore [Argenti B., et al. 2005], 
[Carlotti C.G., et al. 2008]. Questi dati sono confermati da modelli murini che 
riproducono la malattia, in cui sono stati identificate mutazioni a carico di geni 
codificanti proteine appartenenti alla cascata del segnale Shh. In particolare, nel 39% 
dei casi di medulloblastoma è stata riscontrata una delezione allelica sul cromosoma 
17, regione in cui è presente il locus genico codificante RENKCTD11 [Gallo R., et al. 
2002], la proteina sulla quale abbiamo focalizzato la nostra attenzione. Analisi di 
sequenza mostrano che RENKCTD11 presenta all’N-terminale un dominio POZ/BTB: 
attraverso tale dominio interagirebbe con Cul3, promovendo la degradazione di un 
substrato non ancora identificato, che a sua volta regola l’attività del fattore 
trascrizionale Gli1, regolatore della trascrizione dei geni coinvolti nei processi di 
sviluppo. L’oncosoppressore RENKCTD11 potrebbe essere, pertanto, un importante 
target per la progettazione di piccole molecole mimetiche impiegabili a scopo 
terapeutico nel trattamento del medulloblastoma. RENKCTD11 è stata originariamente 
identificata come una proteina di 232 amminoacidi. Allineamenti di sequenza tra 
RENKCTD11 e proteine con struttura tridimensionale nota hanno mostrato che la 
regione N-terminale (residui 20-80) presentava una significativa identità di sequenza 
(circa 40%) con il dominio di tetramerizzazione del canale del potassio Kv4. Questo 
risultato ha suggerito che la forma attiva di RENKCTD11 in vivo potesse essere 
tetramerica. Nessun’altra identità di sequenza è stata rilevata considerando le altre 
regioni della proteina. I numerosi tentativi effettuati per esprimere eterologamente 
RENKCTD11 e suoi mutanti RENKCTD11 in sistemi sia eucariotici che procariotici, hanno 
dato esiti negativi. Successive indagini bioinformatiche hanno evidenziato un aspetto 
peculiare della sequenza N-terminale di RENKCTD11. Allineamenti di sequenza con 
proteine contenenti domini POZ/BTB a struttura nota hanno rivelato, infatti, che il 
dominio POZ/BTB di RENKCTD11 fosse tronco. Considerando la sequenza di 
RENKCTD11 depositata in banca dati, nella proteina è presente solo una porzione del 
core conservato. Allineamenti di sequenza mostrano che manca la parte del dominio 
corrispondente ai foglietti beta B1 e B2 e l’alfa elica A1 secondo il modello proposto 
da Privè [Stogios P.J., et al. 2005]. Questo dato ci ha indotto a valutare la possibilità 
di un alternativo sito d’inizio della traduzione di RENKCTD11. E’ stata da noi 
evidenziata, quindi, una nuova sequenza (forma “lunga”) per RENKCTD11 
caratterizzata da un punto d’inizio della traduzione posto 39 amminoacidi a monte di 
quella precedentemente individuata. L’esistenza della forma “lunga” di RENKCTD11 è 
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stata confermata dagli esperimenti condotti dal gruppo del prof. Alberto Gulino 
(Università “La Sapienza”, Roma). È stata intrapresa, quindi, la caratterizzazione 
biochimica e strutturale della forma “lunga” di RENKCTD11 (271 amminoacidi), 
rivelatasi più stabile rispetto alla forma “corta” originariamente identificata (232 
amminoacidi). RENKCTD11 è stata espressa con diversi partners di fusione e, come 
proteina di fusione con la Maltose Binding Protein (MBP), è stata ottenuta in fase 
solubile; purificata e sottoposta a cromatografia ad esclusione molecolare, rivelando 
che MBP/RENKCTD11 non aggrega e presenta un peso molecolare riconducibile a 
quello di un tetramero, come previsto dai dati raccolti in silico. In seguito a digestione 
proteolitica e successivo allontanamento della MBP, RENKCTD11 tende a precipitare, 
mostrandosi ancora una volta instabile e quindi difficilmente caratterizzabile dal 
punto di vista strutturale. Sono stati quindi intrapresi studi biochimici e strutturali del 
dominio POZ/BTB di RENKCTD11. La ricostruzione del dominio relazionato alla forma 
“lunga” di RENKCTD11 ha richiesto 24 residui amminoacidici a monte del punto d’inizio 
della traduzione della “forma corta”. Tali studi hanno mostrato uno stato di 
organizzazione tetramerico, in accordo con il modello proposto da Privé. Studi di light 
scattering sul POZ/BTB hanno evidenziato un peso molecolare che conferma lo stato 
tetramerico, e un raggio idrodinamico di 4,5 nm, suggerendo una forma globulare. 
Inoltre, studi di dicroismo circolare hanno evidenziato la presenza di α-eliche e 
foglietti β e un’elevata stabilità del dominio (Tm pari a 54 °C), influenzata dalla 
presenza di sali (400 mM NaCl determina un aumento della temperatura di melting di 
5°C). Questo dato è stato utilizzato per mettere a punto prove di cristallizzazione 
dalle quali si sono ottenuti cristalli che diffrangono ad una risoluzione di 4,5 Å, troppo 
bassa per consentire la risoluzione  della struttura. Si è cercato, inoltre, di chiarire il 
preciso ruolo funzionale del dominio POZ/BTB nell’ambito dell’intera proteina. Com’è 
noto, il processo di tetramerizzazione nelle proteine con domini POZ/BTB è 
solitamente favorito dalla presenza di ioni zinco e da interazioni elettrostatiche tra le 
subunità. Studi di allineamento di sequenze hanno rivelato l'assenza nella proteina 
RENKCTD11 degli amminoacidi normalmente responsabili della coordinazione con lo 
zinco; al contrario i residui coinvolti nei ponti salini e nelle interazioni idrofiliche sono 
conservati. Questi dati, unitamente a studi di modelling molecolare, indicano che 
residui amminoacidici specifici possono essere importanti per il processo di 
oligomerizzazione di RENKCTD11. Sulla base di tali informazioni, esperimenti di 
mutagenesi sito-diretta sono stati condotti sul costrutto producendo un tetramutante 
(D69A/R74A/N78A/R81A) che è stato anch’esso clonato ed espresso 
eterologamente in E. coli, per essere poi caratterizzato biochimicamente. In seguito a 
cromatografia ad esclusione molecolare il mutante si è rilevato instabile, suggerendo 
che i residui in esso sostituiti potessero svolgere uno specifico e cruciale ruolo nella 
tetramerizzazione del dominio. Considerando anche il dato precedentemente 
raccolto sullo stato oligomerico della proteina di fusione MBP/RENKCTD11, si è potuto 
affermare che il dominio POZ/BTB è necessario per la strutturazione dell’intera 
proteina RENKCTD11 sotto forma di tetramero. Diversi costrutti di POZ/BTB sono stati 
progettati sulla base di allineamenti di sequenza e predizioni di struttura secondaria, 
nell’intento di inserire ulteriori motivi strutturali e così agevolare il corretto folding del 
dominio ma tali modifiche non hanno apportato i miglioramenti attesi: i prodotti 
ricombinanti ottenuti  si sono dimostrati in parte meno stabili in parte  hanno dato 
cristalli di morfologia diversa rispetto a quelli formati precedentemente, ma 
comunque non in grado di fornire alcun pattern di diffrazione. In seguito ad un’attenta 
analisi degli allineamenti di sequenza, la nostra attenzione si è focalizzata su una 
nuova “open reading frame”, kctd21, che presenta il 40% d’identità con kctd11. Il 
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gene kctd21 è localizzato sul cromosoma 11, che in alcuni rari casi di 
medulloblastoma mostra eventi di delezione allelica e codifica una putativa proteina 
di 260 amminoacidi. Poiché anche in essa è presente un ipotetico dominio POZ/BTB, 
si è pensato di clonare kctd21 e in seguito di esprimere la proteina in E. coli, per 
ricavarne informazioni strutturali che potessero essere estese a RENKCTD11. Pur 
avendo espresso KCTD21 con diversi partners di fusione, la proteina si è mostrata 
sempre instabile in soluzione e quindi anch’essa non caratterizzabile. Per quanto 
riguarda il dominio POZ/BTB di KCTD21, una volta espresso e purificato, si è visto 
che si organizza anch’esso in una struttura tetramerica, ma contrariamente al 
POZ/BTB di RENKCTD11 presenta un’elevata instabilità, che non ha permesso 
successive indagini cristallografiche. I dati fin qui riportati sono stati integrati con 
quelli ottenuti attraverso il modelling molecolare: secondo il modello basato sulla 
struttura già nota del complesso Skp1/Cul1 (omologhe rispettivamente a RENKCTD11 e 
Cul3), ciascuna delle subunità del tetramero di POZ/BTB interagirebbe con una 
molecola di Cul3, formando un complesso di enormi dimensioni a cui si 
aggiungerebbero altri partner d’interazione. Tale modello ha consentito di individuare 
la regione d’interazione tra Cul3 e POZ/BTB: un peptide corrispondente ai residui 49-
68 di Cul3 è stato sintetizzato in fase solida mediante chimica Fmoc ed è stato 
utilizzato per allestire un saggio ELISA con il dominio POZ/BTB di RENKCTD11. Il 
peptide lega POZ/BTB con una costante di affinità apparente di 0,8 µM. Studi NMR 
effettuati tra la proteina marcata con N15 ed il peptide di Cul3 hanno confermato tale 
interazione. Una volta individuata nell’elica 49-68 di Cul3 la regione d’interazione con 
il dominio POZ/BTB da noi studiato, si è cercato di investigare se la stessa regione di 
Cul3 fosse responsabile dell’interazione con i domini POZ/BTB di altri membri della 
famiglia di proteine KCTD. Si è scelto come  membro di tale famiglia KCTD5 la cui 
struttura cristallografica è stata recentemente depositata  [Dementieva I. S., et al. 
2009]. Tramite un saggio ELISA si è verificato che anche il dominio POZ/BTB di 
KCTD5 è in grado di legare l’elica 49-68 di Cul3 con un’affinità apparente 
paragonabile a quella del dominio POZ/BTB di RENKCTD11. Attualmente, sono state 
allestite prove di co-cristallizzazione con l’elica Cul3, allo scopo sia di identificare la 
regione del dominio POZ/BTB di KCTD5 coinvolta nell’interazione, che di ottenere 
informazioni utili alla caratterizzazione dell’interazione del dominio POZ/BTB di 
RENKCTD11 con Cul3. Grazie alla consistente mole di dati fin qui raccolti, è stato 
possibile far luce sui complessi meccanismi molecolari che sono alla base dell’attività 
biologica di RENKCTD11 nell’ambito del signaling Hedgehog e di identificare nell’elica 
di Cul3 un potenziale “scaffold” di interesse  terapeutico. 
 
10 
 
1 Introduction 
 
1.1 POZ/BTB Domain 
 
The BTB domain (also known as the POZ domain) was originally identified as a 
conserved motif present in the Drosophila melanogaster bric-à-brac, tramtrack and 
broad (BTB) complex transcription regulators and in many poxvirus zinc finger (POZ) 
proteins. BTB/POZ domain is typically found in a single copy per protein, but in some 
proteins it is combined with a variety of additional protein-protein interaction domains, 
such as the kelch repeats, MATH domains, ankyrin repeats, the b-zip DNA binding 
domain and FYVE fingers [Bardwell V. J., et al. 1994], [Zollman S., et al. 1994]. 
Additionally, all the mammal potassium channels contain POZ (T1) domains in their 
N-terminus. BTB/POZ combining with a number of other domains forms a variety of 
distinct domain architectures (figure 1.1). Among the most common ones is the 
combination of the BTB/POZ domain with C-terminal zinc fingers. This domain 
architecture is abundantly represented in Drosophila and in vertebrates, and the 
respective proteins are typically involved in transcriptional regulation and chromatin 
remodelling. Given the extremely wide representation and functional significance of 
BTB/POZ domains, the structural basis of these interactions is of major interest. The 
biological properties of BTB/POZ-containing proteins seem to be contingent on the 
protein-protein interaction properties of this domain. Several lines of research have 
uncovered distinct roles for these proteins in diverse cellular locations. In particular, 
BTB/POZ domains appear to participate in a variety of processes ranging from 
transcriptional repression/activation to cytoskeletal organization. In several proteins, 
BTB/POZ domains have been shown to mediate homodimerization or multimerization 
[Aravind L., et al. 1999]. Several BTB/POZ structures have been determined by X-ray 
crystallography, establishing the structural similarity between different examples of 
the fold [Ahmad K. F., et al. 1998], [Kreusch A., et al. 1998]. A comparison of the 
solved structures of BTB domains from the Protein Data Bank (PDB), which included 
examples from BTB-ZF proteins, Skp1, ElonginC and T1 domains showed a common 
region of approximately 95 aminoacids consisting of a cluster of 5 α-helices made up 
in part of two α-helical hairpins (A1/A2 and A4/A5), and capped at one end by a short 
solvent-exposed three stranded β-sheet (B1/B2/B3), (figure 1.2 a). An additional 
hairpin-like motif consisting of A3 and an extended region links the B1/B2/A1/A2/B3 
and A4/A5 segments of the fold. Because of the presence or absence of secondary 
structural elements in certain examples of the fold, they used the designation A1–A5 
for the five conserved α-helixes, and B1–B3 for the three common β-strands. We 
refer to this structure as the core BTB fold. When present, other secondary structure 
elements are named according to the labels assigned to the original structures. Thus, 
the BTB-ZF family members, the promyelocytic leukemia zinc finger (PLZF) and B-
cell lymphoma 6 (BCL6) contain additional amino-terminal elements, which are 
referred to as β1 and α1, Skp1 protein contains two additional carboxy-terminal 
helixes labelled α7 and α8, ElonginC is missing the A5 terminal helix, and the T1 
structures from Kv proteins are formed entirely of the core BTB fold (figure 1.2 b). 
Thus, the BTB domain in BTB-zinc finger (ZF), Skp1, ElonginC and voltage-gated 
potassium channel T1 (T1-Kv) proteins all contain the BTB fold, even though some of 
these differ in their peripheral secondary structure elements and are involved in 
different types of protein-protein associations. For example, BTB domains from the 
BTB-ZF family contain an amino-terminal extension and form homodimers, whereas 
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the Skp1 proteins contain a family-specific carboxy-terminal extension and occur as 
single copies in heterotrimeric SCF complexes. The ElonginC proteins are also 
involved in protein degradation pathways, although these proteins consist only of the 
core BTB fold and are typically less than 20% identical to the Skp1 proteins. Finally, 
T1 domains in T1-Kv proteins consist only of the core fold and associate into 
homotetramers. Thus, while the structures of BTB/POZ domains show good 
conservation in overall tertiary structure, there is little sequence similarity between 
members of different families. As a result, the BTB/POZ fold is a versatile scaffold 
that participates in a variety of types of family-specific protein-protein interactions 
[Stogios P. J., et al. 2005]. More recently, some BTB proteins have been 
characterized as substrate-specific adaptors for cullin(CUL)3-based E3 ligases. The 
BTB/POZ domain of these substrate-specific adaptors, in particular, binds to Cul3. In 
mammalian cells, a few other BTB/POZ proteins, e.g. SPOP, a BTB-MATH protein, 
and KEAP1, a BTB-KELCH protein, have been described as adaptors of Cul3-based 
E3 ligases [Kwon J.E., et al. 2006], [Zhuang M., et al. 2009]. 
 
 
 
 
 
Figure 1.1. Domain architectures of the POZ/BTB-containing proteins [Aravind L., et al. 1999]. 
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Figure 1.2. Comparison of structures containing the BTB/POZ fold: (a) superposition of the BTB/POZ 
core fold from currently known BTB/POZ structures. The BTB/POZ core fold is retained across four 
sequence families. The BTB-ZF, Skp1, ElonginC and T1 families are represented by the domains from 
Protein Data Bank (PDB) structures; (b): schematic of the BTB/POZ fold topology. The core elements 
of the BTB/POZ fold are labelled B1 to B3 for the three conserved β-strands, and A1 to A5 for the five 
α-helixes. Many families of BTB/POZ proteins are of the 'long form', with an amino-terminal extension 
of α1 and β1. Skp1 proteins have two additional α-helices at the carboxyl terminus, labelled α7 and 
α8. The dashed line represents a segment of variable length that is often observed as strand β5 in the 
long form of the domain, and as an α-helix in Skp1 [Stogios P.J., et al. 2005]. 
 
 
 
1.2 Potassium Channel Tetramerization Domain (KCTD) Proteins 
 
The human genome has 21 kctd genes that encode potassium channel 
tetramerization domain containing (KCTD) proteins. kctd genes are so named 
because the N-terminus of KCTD proteins and some voltage-gated K+ (Kv) channels 
are homologous. KCTD proteins are soluble with N-terminal BTB/POZ domains and 
variable C-terminal. The 21-kctd genes predict proteins that can be sorted into seven 
groups based on the alignment of their N-terminal sequences. Some kctd genes are 
single-exon loci (4, 11, 12, and 14), while others appear to be subject to splice 
variation that would increase diversity. Group I contains KCTD 2, 3, 5, 9, and 17. 
KCTD5 is most closely related to KCTD2 and KCTD17, while KCTD3 and KCTD9 
display ~ 60% similarity to the KCTD5 N-module and have dissimilar C-terminal. The 
N-module of KCTD5 displays 20% identity to the T1 domains of Kv1, Kv2, Kv3, and 
Kv4 channels (figure 1.3). The biological function of KCTD proteins remains unclear. 
High expression of transcripts in foetal tissues and low levels in adults suggest that 
they play a role during development. Thus, KCTD12 is implicated in the maturation of 
inner ear neurons by linkage to a progressive dominant auditory neuropathy; 
KCTD11 is proposed to suppress Hedgehog signalling and to promote tumour growth 
in medulloblastoma. A point mutation in KCTD7 has been associated with 
neurodegeneration and progressive myoclonic epilepsy, and KCTD5 has been 
reported to interact with human Golgi reassembly stacking protein 55 (GRASP55) 
[Dementieva I. S., et al. 2009]. 
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Figure 1.3. Phylogenetic tree built from human paralogs of KCTD5 [Bayon Y., et al. 2008]. 
 
1.3 KCTD5 
 
KCTD5 has been reported to interact with human GRASP55. GRASP proteins 
contribute to the stacked organization of Golgi cisternae and are thought to 
participate in protein trafficking [Shorter J. et al. 1999]. KCTD5 has been the first 
member of the family KCTD to be characterized so far. The structure reveals a 
pentameric assembly with N- and C-modules and a central complex-spanning cavity. 
The high sequence identity of N-terminus (70%) of KCTD5 with the N-terminus of 
KCTD2 and KCTD17 suggests that the latter will also form pentameric assemblies. 
One KCTD5 pentamer is assembled with one GRASP55 monomer with an apparent 
equilibrium affinity of ~1 μM. KCTD5 binds to both full-length GRASP55 and the 
GRASP55 N-terminal domain (residues 1–263) with micromolar affinity. An intact 
KCTD5 C-module is required to bind GRASP55, while the pentameric KCTD5 N-
module (residues 40–145) binds neither full-length nor truncated GRASP55. KCTD5 
interacts specifically with Cul3, and forms oligomers through its BTB domain. 
Analysis of the interaction with Cul3 showed that, the C-terminal region of KCTD5 
was dispensable for this interaction, while the BTB/POZ domain interacted with 
additional five aminoacids (40-45) on the N-terminus. Studies with other BTB/POZ 
proteins, e.g. SPOP [Zhuang M., et al. 2009], have also shown that other parts of 
their sequence, in addition to the BTB/POZ domain, are involved in the association 
with Cul3. On the other hand, the Cul3 region involved in this interaction was the N-
terminus, as described for other BTB/POZ proteins. Taking into account that KCTD5 
could be an adaptor of Cul3 E3 ligases, it was hypothesized that the region C-
terminal could participate in substrate recognition, and that this could be a new 
protein interaction domain conserved through evolution. The fact that KCTD5 can 
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form oligomer through its BTB/POZ domain and the recent description of 
heterodimerization of Cul3 would indicate that complexes of higher order could be 
formed between Cul3 and BTB substrate adaptors, implying the recruitment of a 
great number of substrates by these E3 ligases. The same BTB surfaces, recently 
demonstrated, mediate pentamer and tetramer formation in KCTD5 and Kv channels, 
respectively, while BTB motifs had previously been demonstrated to mediate 
aggregation of two and four subunits via separate portions of the domain. These 
findings suggest that KCTD5 is a substrate-specific adaptor for Cul3-based E3 
ligases [Bayon Y., et al. 2008], [Dementieva I. S., et al. 2009]. 
 
 
1.4 E3 ubiquitin-protein ligases 
 
Ubiquitin-dependent proteolysis regulates protein abundance and serves a central 
regulatory function in many biological processes. Ubiquitination is involved in a wide 
range of cellular functions, such as cell proliferation, differentiation, and apoptosis, 
mainly by targeting proteins for degradation by the 26S proteasome, but it is also 
involved in protein transport and signalling through additional mechanisms. The 
ubiquitination of a target protein is mediated by the ubiquitin–protein ligases, which 
represent a diverse super-family of proteins and protein complexes. The SCF (Skp1–
Cullin–F-box protein) and SCF-like complexes are the largest family of ubiquitin–
protein ligases and ubiquitinate a broad range of proteins involved in cell cycle 
progression, signal transduction and transcription [Zhou P., et al. 1998]. Deregulation 
of SCF-dependent proteolysis can contribute to neoplastic transformation. Ubiquitin-
protein ligases (also known as E3s) act at the last step of a three-enzyme cascade 
involving the ubiquitin-activating (E1) and ubiquitin-conjugating (E2) enzymes. The 
E3 mediates the transfer of ubiquitin from the E2 to the substrate protein by 
promoting the formation of an isopeptide bond between the ubiquitin (Ub) carboxy-
terminus and specific lysine side chains on the substrate. E3s bind both the protein 
target and a cognate E2 and have a central role in conferring specificity to the 
ubiquitination pathway. Two functionally distinct types of E3s have been identified: 
HECT-type E3s catalyse ubiquitination by first forming an E3–ubiquitin thioester 
intermediate, RING-type E3s do not appear to form such an intermediate. The 
mechanism by which they promote ubiquitination has not been well understood. The 
crystal structure, recently solved, highlights an elongated structure with Rbx1 and the 
Skp1–Fbox-Skp2 complex segregated to opposite ends (figure 1.4). This 
arrangement is organized by Cul1, which interacts with all three subunits and serves 
as a scaffold. Cul1 consists of a 415 aminoacids with a N-terminal helical region, N-
terminal domain (NTD), that adopts a long stalk-like structure and binds the Skp1–
Fbox-Skp2 complex, and a 360 aminoacids C-terminal globular domain (CTD) that 
binds Rbx1. The Cul1 NTD stalk consists of three repeats of a novel five-helix 
structural motif (the cullin repeat). The three cullin repeats are arranged in a regularly 
repeating fashion resulting in an arc-shaped structure spanning, 110 A° (figure 1.4). 
The N-terminal tip of the first repeat binds the Skp1–Fbox-Skp2 complex. At the 
opposite end the C-terminal two helixes of the third repeat pack with a four-helix 
bundle from the Cul1 CTD. The CTD structure consists of a four-helix bundle (4HB), 
an a/b domain with an intermolecular five-stranded b-sheet, which contains as its 
second strand an N-terminal segment of Rbx1, and two copies of the winged-helix 
motif (WH-A and WH-B); the Cul1 CTD contains several structural units that 
assemble around the Rbx1 protein to form a single globular unit. Part of the Cul1 
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CTD forms a five-stranded intermolecular b-sheet that contains as its second b-
strand an N-terminal sequence of Rbx1. The rest of the Cul1 CTD forms a 30 A° wide 
groove wherein the Rbx1 RING domain is embedded. The RING domain of Rbx1 is a 
variant of the canonical RING motif, with a 20 aminoacids insertion that forms a third 
zinc coordination site. Cul1 is modified through the covalent attachment of the 
ubiquitin like small molecule Nedd8. Cul1 is neddylated at Lys 720, which is on the 
WH-B domain and is positioned at the rim of a cleft formed by conserved residues 
from the WH-B, 4HB and Rbx1 RING domain The N-terminal tip of the first repeat 
binds the Skp1–Fbox-Skp2 complex. The proximity of Lys 720 to the Rbx1 RING 
domain supports the model that Nedd8 might modulate the binding and positioning of 
the E2 or the E2–ubiquitin conjugate  [Zheng N., et al. 2002]. The large number of F-
box proteins in eukaryotic genomes is thought to allow for the specific ubiquitination 
of a large number of functionally and structurally diverse substrates [Schulman B. A., 
et al. 2000], [Cardozo T., et al. 2004]. In the canonical example of Cul1, substrate 
receptors are recruited by the adaptor protein Skp1. Skp1 is divided into two 
domains: an N-terminal segment that binds Cul1 and a C-terminal region that binds 
the F-Box motif of substrate receptors (figure 1.5 a). The N-terminal segment of Cul1 
that contacts Skp1 is highly conserved among Cul1 orthologues from different 
species, but not among other cullins, which reveals a structural basis for how each 
cullin specifically recruits a different set of substrates. Skp1 interacts selectively with 
Cul1 and Cul7. However, the adaptor proteins that are used by other cullins show 
considerable structural homology to Skp1. The cullin-binding region of elongin C, 
which binds Cul2 and Cul5 (figure 1.5 b), shares with Skp1 a fold that was first 
observed for the BTB/POZ domain. This indicated that BTB-domain proteins might 
be adaptors for a RING-type E3s, and this has now been shown to be the case for 
several BTB-domain proteins, which bind specifically to Cul3 (figure 1.5 c). The most 
poorly understood adaptor protein, DNA damage-binding protein-1 (DDB1), is not 
related to Skp1, elongin C or BTB domains, so it is unclear how it links substrate 
receptors to Cul4A [Kamura T., et al. 1998], [Furukava M., et al. 2003]. 
 
 
 
Figure 1.4. Overall structure of the Cul1–Rbx1–Skp1–F boxSkp2 quaternary complex. Cul1, Rbx1, 
Skp1 and the F-box of Skp2 are coloured in green, red, blue and magenta, respectively. The five 
helices that make up the cullin-repeat motif are labelled for the second repeat [Zheng N., et al. 2002]. 
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As DDB1 is a much larger protein than Skp1 and elongin C, it might somehow 
compensate for the shorter length of the N-terminal stalk region of Cul4A (Figure 1.5 
d). Cullin can assemble with numerous substrate receptors to form ubiquitin ligases 
that share a common catalytic core yet recruit different substrates. These receptors 
typically contain an N-terminal domain that binds an adaptor and a C-terminal region 
that binds substrate. Two distinct adaptor-binding domains are known: F-boxes binds 
Skp1, which, in turn, binds Cul1 and Cul7; whereas suppressor of cytokine 
signalling/elongin-BC (SOCS/BC) boxes binds elongin BC, which, in turn, binds Cul2 
and Cul5 (figure 1.5 a, b). For Cul3-based ligases, the adaptor and substrate 
receptor functions are merged into a single polypeptide that binds Cul3 directly 
through an N-terminal BTB domain and the substrate through a C-terminal domain 
(figure 1.5 c). Substrate receptors that are recruited to DDB1–Cul4A do not share an 
obvious motif (figure 1.5 d). Cul3 is capable of interacting with a variety of BTB 
proteins, analogous to Cul1, which interacts with various F-box proteins. The fact that 
multiple BTB-domain proteins interact with Cul3 and that many BTB-domain proteins 
also contain additional protein interaction domains points to the possibility that BTB 
proteins function directly as adaptors that recruit substrates to Cul3, thereby forming 
an SCF-like E3. It is possible to identify a family of BTB-domain proteins as 
substrate-specific receptor modules for Cul3-based E3 ligases. BTB proteins contain 
a variety of putative protein interaction domains, including MATH domains, WD40 
repeats, Zn finger repeats and kelch repeats. It was found that human BTB proteins 
containing MATH and kelch domains, as well as BTB-only proteins, interact with 
human Cul3. Although most BTB-domain proteins contain additional known protein 
interaction domains, approximately 30% lack recognizable domains and may have 
specialized protein interaction domains to recruit substrates or be substrates 
themselves, like some F-box proteins. Given the number of F-box, BC-box and BTB 
proteins in eukaryotes, SCF-like complexes seem to have the potential to control an 
extremely large number of signalling events through the ubiquitin–proteasome 
pathway. Although initially used to designate Skp1–Cul1–F-box protein complexes, 
the term SCF can be used conceptually in the description of a larger collection of 
cullin-based E3 ligases. Each SCF-like complex contains, in addition to the common 
catalytic core, a modular substrate-specific receptor that possesses structural 
homology with Skp1 and functional homology with C-terminal substrate interaction 
domains of F-box proteins. In addition, some SCF complexes contain further 
components, for example, elongin B in the case of Cul2 and Cul5 complexes [Xu L., 
et al. 2003], [Kwon J. E., et al. 2006], [Bayon I., et al. 2008]. 
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Figure 1.5. The modularity of cullin–RING ligases. Although the N-terminal region is thought to be 
similar in structure between family members, a segment of it is variable in sequence (red), and cullins 
use this region to interact with their own specific adaptor proteins. The motifs that link substrate 
receptors to their cognate adaptors are shown in yellow. In addition to an adaptor-binding motif, 
substrate receptors contain a second protein–protein interaction motif that binds to the targeted 
substrate (substrate interaction motif (SIM), which is shown in brown); a: Cul1 CRLs, which are known 
commonly as Skp1, Cul1, F-box (SCF) proteins, recruit substrates through the adaptor protein Skp1 
and an F-box-protein substrate receptor. b: Cul2 and Cul5 CRLs recruit substrates through an elongin-
BC adaptor and a suppressor of cytokine signalling/elongin BC-box-protein substrate receptor 
(labelled SOCS in the figure). c: Cul3 CRLs recruit substrates through BTB-domain-containing 
substrate-receptor proteins. d: Cul4A CRLs might recruit substrates through the adaptor protein DNA 
damage-binding protein-1 (DDB1), which interacts with Cul4A using an unknown motif [Petroski M.D., 
et al. 2005]. 
 
 
1.5 Sonic Hedgehog pathway 
 
Hedgehog (Hh) proteins are secreted glycoproteins that activate a membrane-
receptor complex that, in turn, activates Gli zinc-finger transcription factors. Hh 
proteins are synthesized as 45-kDa precursors, consisting of an N-terminal signalling 
domain and a C-terminal catalytic domain. An important feature of these proteins is 
their post-translational processing involving lipid modification of their two terminals, 
increasing the hydrophobicity and influencing the movement of Hh proteins between 
cells. In mammals, the Hh family consists of three members: Sonic hedgehog (Shh), 
Indian hedgehog (Ihh), and Desert hedgehog (Dhh). Dhh is required for 
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spermatogenesis and also is secreted by Schwann cells where it is important for the 
formation of the perineurial sheath and maintenance of trophic signals in peripheral 
nerves. Shh and Ihh share same overlapping roles in regulating left–right asymmetry, 
neural tube development, and the formation of a variety of organs including the bony 
skeleton, but they also have different properties. Ihh is critical in mediating the 
communication between the uterine epithelium and stroma required for embryo 
implantation. Shh plays an active role in the formation of the central nervous system 
(CNS), especially the cerebellum, and is responsible for midline facial development 
and the induction of neural tissue by mesodermal notochord [Palma V., et al. 2004], 
[Palma V., et al. 2005]. The Shh-Gli pathway has been the focus of much recent 
attention, and the positive action of the pathway is tightly regulated at different levels 
by many inhibitors. For example, Shh signalling activates a receptor complex that is 
formed by Patched (Ptc) and Smoothened (Smo) [Huangfu D., et al. 2006]. Hh 
inhibits Ptc, which, in turn, normally inhibits Smo. Inhibition of Ptc by Hh activates the 
Hh pathway and results in Gli activity. The function of Ptc, and other inhibitors, is to 
silence the pathway in the absence of active Hh ligands. This implies that the Hh–Gli 
pathway must be off most of the time, and only active at the precise points and 
locations at which the Hh signals act. Gli proteins are large multifunctional 
transcription factors, and their activities are intricately regulated. They reside in both 
the nucleus and the cytoplasm, where they are components of a multimolecular 
complex that is tethered to the cytoskeleton. The state of Shh signalling directly 
affects the fate of Gli proteins. In the absence of Shh, Gli proteins are cleaved by the 
proteasome, and carboxy-terminally truncated forms translocate to the nucleus, 
where they act as dominant transcriptional repressors. Following Shh signalling, Gli 
repressor formation is inhibited and full-length labile activators of transcription are 
made instead (figure 1.6). The three Gli proteins behave differently. In addition to 
being transcriptionally regulated in different ways, Gli1 does not seem to yield a 
strong repressor, whereas Gli2 and Gli3 do. Shh inhibits repressor formation by Gli3, 
but not by Gli2, and the formation of potent activators of Gli2, and perhaps of other 
Gli proteins, depends on Hh signalling. Gli proteins have partially redundant and 
partially distinct functions and induce distinct targets indicating that they act in a 
combinatorial manner that is context dependent and, possibly, species-specific. The 
generation of transcription repressor forms and degradation of activator forms 
represent an important control of Hh signaling output and occur via multiple 
proteolytic processing mechanisms involving a dual Cullin based and a HECT-based 
ubiquitin-dependent pathways. In the absence of Hh signal, phosphorylation at 
multiple sites of Gli2 and Gli3 by PKA, GSK3 and CKI, enables the recruitment of the 
E3 ubiquitin ligase belonging to the SCF complex including the F-box protein bTrCP, 
Skp1, Cul1 and Rbx1 proteins. The subsequent proteolytic processing generates 
truncated Gli2 and Gli3 provided of transcription repressor function. Additional 
molecules influence in a positive and negative way the signalling pathway. Some of 
the negative regulators have been described to be relevant in Hh pathway-dependent 
diseases such as brain tumours. For instance, suppressor of fused (SUFU) binds Gli 
proteins thereby inhibiting nuclear accumulation and interfering with their 
transcriptional activity [Taylor M. D., et al. 2002]. The Shh–Gli pathway seems to 
regulate many processes in cells. For instance, it can regulate survival in both 
differentiated and undifferentiated cell types, induce floor-plate differentiation and 
induce proliferation of neuron precursors in the developing cerebellum. Shh controls 
the growth of the cerebellum, and it orchestrates the positioning and differentiation of 
several cell types. Among other functions, Shh promotes proliferation of granule-
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neuron precursors in the external germinal layer (EGL) of the cerebellum. 
Medulloblastomas are predicted to arise when granule-neuron precursors 
inappropriately maintain an active Shh–Gli pathway and express Gli1. Normally, this 
signalling and patterning information is tightly regulated and when it persists 
inappropriately, precursor cells might be instructed to proliferate abnormally, thereby 
initiating a tumour. The regulation of proliferation in the EGL has two conflicting 
tasks: to fulfil the need for the cerebellum to grow to the appropriate size for a given 
species, while preventing tumorigenesis. Endogenous secreted factors that might 
regulate the time at which outer EGL cells stop cycling could be useful as anticancer 
agents. A clear molecular understanding of how the Shh–Gli pathway operates in the 
cerebellar cortex is likely to not only reveal how this CNS organ is formed, but also 
provide clues for possible rational therapies [Ruiz i Altaba, et al. 2002], [Rubin L. L., 
et al. 2006], [Gulino A., et al. 2007]. 
 
 
 
 
 
Figure 1.6. Mechanisms of activation of Hegehog signalling. In the absence of hedgehog ligand in the 
receiving cell (Off-state), the receptor for hedgehog-family ligands, patched, represses the activity of 
another transmembrane protein called smoothened. In the On-state, hedgehog binding to Patched 
leads to activation and translocation of Smoothened to the primary cilium. Consequently, the 
conserved action of hedgehog ligands is to switch the Gli-factors from being transcriptional repressors 
to activators [Cell signalling technology©]. 
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1.6 Medulloblastoma (MB) 
 
Survival rates of pediatric brain tumour patients have significantly improved over the 
years due to developments in diagnostic techniques, neurosurgery, chemotherapy, 
radiotherapy, and supportive care. However, the causes of pediatric brain tumours 
are largely unknown. Environmental factors, such as smoking, diet, and other 
exposures, do not predispose the brain to develop tumours. Only a very small 
proportion of brain tumours are caused by hereditary gene defects, irradiation, or 
immune suppression. Medulloblastomas are the most common cerebellar tumours of 
central nervous system in childhood. They are neuroepithelial tumours arising from 
the cerebellum and account for ~20% of all intracranial tumours in children, and for 
40% of all childhood posterior fossa tumours [Crawford J. R., et at. 2007]. Although 
medulloblastoma peaks at 8 years of age, ~ 30% of medulloblastomas occur in 
adults. Historically, medulloblastomas and other central nervous system embryonal 
tumours are classified on the basis of their location and of their histological features 
[Ellison D. 2002], [Rossi A., et al. 2008]. Although most medulloblastomas occur 
sporadically, some may arise within patients with known familial cancer syndromes. 
As a group, the familial cancer syndromes provide us with clues regarding embryonic 
alterations in key signalling or growth factor activation pathways that must be 
involved in the pathogenesis of medulloblastoma. As a rule, these growth factor 
families, including Hh, Wnt, and Notch pathways, control embryonic patterning and 
cell fate determination in species ranging from Drosophila to humans (figure 1.7) 
[Dahmane N., et al. 1999], [De Bont J. M., et al. 2008] [Wechsler Reya R., et al. 
2001]. They also regulate the development of the cerebellum including the 
proliferation of the granule cells in the external granular layer, the site of origin of at 
least a subset of medulloblastomas. In addition, there is now strong evidence that 
suggests that normal embryogenesis and tumourigenesis share many properties 
involving alterations in cell proliferation, differentiation, motility, angiogenesis, 
apoptosis, and stem cell control. It is commonly believed now, and in fact has been 
shown, that certain genes that are involved in normal neuro-embryogenesis, if 
deregulated, will contribute to medulloblastoma formation [Carlotti Jr C.G., et al. 
2008]. Several observations suggest that alterations of molecular events regulating 
the development of cerebellum are responsible for uncontrolled cell growth, 
eventually leading to medulloblastoma formation. The cerebellum is composed of 
different cell layers, including granule cells and Purkinije cells. During development, 
cerebellar granule cell progenitors GCPs migrate from the rhombic lip over the outer 
layer of the cerebellar surface (external granule layer); after an initial burst of cell 
proliferation, they start a differentiation program by exiting the cell cycle and moving 
into the inner EGL. They migrate farther inward into the internal granule layer (IGL), 
where differentiated granule neurons reside. There is considerable evidence that 
factors secreted by Purkinije cells regulate the proliferation of GCPs in the EGL. In 
particular, Purkinije cells secrete Sonic Hedgehog (Shh) that is involved in the initial 
EGL cell population expansion and is the most potent mitogen for GCPs, whereas 
what causes GCPs to stop dividing in the inner EGL is not well understood. 
Importantly, failure to contain the proliferation of developing GCPs is involved in 
tumorigenesis, because constitutive activation of the Hedgehog pathway is 
responsible for medulloblastoma development (figure 1.8) [Wechsler Reya R.J., et al. 
1999], [Ruiz et Altaba A., et al. 2002], [Lai K., et al. 2003], [Argenti B., et al. 2005], 
[Thompson M. C., et al. 2006], [Carlotti C. G., et al. 2008]. Among the different 
alterations observed in medulloblastoma, the most frequent one is represented by 
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allelic deletion on the short arm of chromosome 17, occurring in up to 50% of 
tumours and frequently restricted to a common region at 17p13.2-13.3. However, the 
identification of candidate tumour suppressors located in this region has been so far 
elusive. p53, one of the most important tumour suppressor genes, was initially 
suggested to be of importance in medulloblastoma, because it is localized on 
chromosome region 17p13. However, it is shown that the incidence of p53 mutations 
in sporadic medulloblastoma is low. Besides p53, several other candidate tumour 
suppressor genes on 17p have been suggested. Interestingly, 17p carries several 
genes suggested to be involved in the regulation of SHH signalling. renKCTD11, a 
putative tumour suppressor gene located on chromosome 17p13.2, is deleted in 39% 
of medulloblastomas. RENKCTD11 is haplo-insufficient in several human MB, as a 
consequence of allelic deletion, in association with down-regulated expression [Di 
Marcotullio L., et al. 2004], [De Smaele E., et al. 2004], [Ferretti E., et al. 2005]. 
Additional knowledge about the biological characteristics of pediatric brain tumours 
may provide new information about pathogenesis, facilitate diagnosis, contribute to 
better risk-group stratification for therapy, or be used to develop new therapeutic 
targets. A major hope for the future is that the incorporation of biological agents 
targeting specific signalling pathways will not only make treatment more effective, but 
also allow a reduction in neurotoxic therapy [Gilbertson R. J., 2004], [Marino S., et al. 
2005], [Grill J., et al. 2007]. 
 
 
 
 
 
Figure 1.7. Signalling pathways involved in the development of the brain and pathogenesis of 
medulloblastoma. Interactions among these pathways are multiple and complex. Deregulation of these 
pathways is important in the pathogenesis of medulloblastoma [De Bont J.M., et al. 2008]. 
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Figure 1.8. In neuro-embryogenesis the cerebellum is comprised of external granule cell and Purkinje 
cell layers. What ensues at birth is a proliferation of external granule cells as induced by Shh as 
secreted by the Purkinje cells. Then, there is differentiation and migration of the external granule cells 
as they move past the Purkinje cells to help form the internal granule cell layer. In the context of 
overactive Shh signalling, there is uncontrolled proliferation of the external granule cells with 
medulloblastoma formation [Carlotti C.G., et al. 2008]. 
 
 
 
1.7 RENKCTD11 
 
RENKCTD11 (retinoic acid (RA), epithelial growth factor (EGF) and nerve growth factor 
(NGF) responsive gene) represents a novel component of the neurogenic signalling 
cascade and is both a marker and a regulator of neuronal differentiation. The 
sequence exhibits no significant homology with previously described murine or 
human genes nor carries putative functional domains observed in other classes of 
proteins, with the exception of a BTB/POZ motif located at the N-terminus between 
amino acid residues 21 and 77 (figure 1.9 and 1.10). RENKCTD11 regulation is at the 
cross-roads of several neurogenic signals characterized by diverging outputs. 
RENKCTD11 expression is specifically enhanced by EGF receptor/ErbB1-generated 
signals that are reported to regulate cerebellar development, being involved in all 
phases of neurogenesis, including enhanced proliferation of EGL granule progenitors 
and their migration and differentiation phases. RENKCTD11 is up regulated by RA and 
NGF also that, conversely, promote growth arrest and neuronal differentiation [Gallo 
R., et al. 2002]. Consistent with these observations, RENKCTD11 expression is mainly 
restricted to embryonal life and is developmentally regulated. An active role in 
neurogenesis is suggested by the ability of RENKCTD11 to promote neural cell growth 
arrest and to antagonize EGF-induced mitogenesis and neuronal differentiation of 
neural progenitors. A dysfunctional RENKCTD11 is expected to be associated with 
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medulloblastoma. RENKCTD11 is a candidate for playing such a role in EGL 
development, as suggested by the following evidence. First, RENKCTD11 expression 
inversely correlates with granule cell proliferation along the transition from outer to 
inner EGL GCPs and in IGL cells of the developing cerebellum. Such a cell 
maturation process in vivo is paralleled by the up regulation of RENKCTD11 expression 
also occurring along GCP differentiation in culture. Second, RENKCTD11 is able to 
inhibit Shh-dependent events, thus antagonizing both Shh induced growth and block 
of differentiation of cultured GCPs. Finally, an active role for RENKCTD11 is also 
suggested by the requirement of RENKCTD11 expression to restrain Hedgehog 
signalling and cell growth and to promote the differentiation of cultured GCPs. These 
observations strongly support the notion that RENKCTD11 may be involved in the 
control of the expansion of GCPs during the transition from outer to inner EGL 
(Argenti B., et al. 2005). The loss of function of RENKCTD11, as a consequence of 
cancer associated genetic–epigenetic events, might relieve a restraint of Hedgehog 
signalling at the transition from outer to inner EGL GCP and withdraw a limiting signal 
for immature cell expansion, thus favouring tumourigenic events. Indeed, has been 
recently reported that human RENKCTD11 is haplo-insufficient (as a consequence of 
hemizygosity and significantly reduced expression with respect to normal cerebellar 
tissue) in all medulloblastomas bearing the 17p loss, while downregulated expression 
is observed also in bi-allelic tumours. Treatment with the demethylating agent 5’-
azacytidine restores higher levels of gene expression, suggesting that the low 
RENKCTD11 expression is also due to active gene silencing in medulloblastoma. 
Interestingly, the inappropriate activation of HH signalling detected in 
medulloblastoma cells is specifically targeted by RENKCTD11 which inhibits cell growth 
by antagonizing Gli1-mediated transactivation of HH target genes via impairment of 
Gli1 nuclear transfer. Therefore, RENKCTD11 is a novel suppressor of HH signalling 
and its inactivation, due to 17p loss, might lead to a deregulation of the tumour 
promoting HH pathway. RENKCTD11 inhibits medulloblastoma cell proliferation by 
antagonizing the activation of SHH target genes. Deletion of this gene might thus 
result in enhanced SHH signalling and increased proliferation of granule cell 
precursors (figure 1.11) [Di Marcotullio L., et al. 2004] [De Smaele E., et al. 2004]. 
 
 
 
Figure 1.9. Sequence alignment of RENKCTD11 and Kv4 tetramerization domain. 
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Figure 1.10. Fragments of REN
KCTD11
 that show significant sequence similarity with proteins with 
known 3D structure. 
 
 
 
 
 
Figure 1.11. Hedgehog antagonists encoding genes mapping to chromosome 17p13.2.13.3. 17p-
associated Hedgehog antagonist gene products suppress Gli nuclear transfer (REN
KCTD11
) or the 
function of Hedgehog target genes [Ferretti E., et al. 2005]. 
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1.8 The aim of the work 
 
RENKCTD11 represents a restraint of Shh signalling and its loss of function might 
favour tumorigenesis. Since no information is available in the literature on the 
structure of RENKCTD11, the aim of this PhD thesis has been the biochemical 
characterization of this protein. Subsequently, on the basis of sequence identity 
found between the N-terminal RENKCTD11 domain (POZ/BTB) and the tetramerization 
domain of the potassium channel KV4, a three-dimensional model was designed for 
the N-terminal region of the protein, to identify aminoacid residues of RENKCTD11 
crucial for the oligomerization status, stability and interaction with its partner Cul3. 
RENKCTD11 function carries on through a network of protein-protein interactions finely 
regulated. So, a further aim of this project has been to provide the structural basis for 
the design of small molecules that mimic the biological activity of RENKCTD11 and to 
test them by immunological assays and NMR studies. Moreover, other POZ/BTB 
proteins, like KCTD5, have been object of this thesis in order to evaluate the 
biotechnological application of the identified molecules as agonist or antagonist of 
KCTD proteins involved in de-regulated pathways. 
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2 MATERIALS AND METHODS 
 
2.1 Strains, enzymes, reagents and instruments 
 
Reagents used for preparation of buffers and growth media of Escherichia coli and 
the reagents for polyacrylamide gels electrophoresis (Acrylamide, APS, TEMED, 
SDS, Tris, Glycine) were supplied by Sigma Aldrich, Euroclone, Applichem and ICN 
Biomedicals. The molecular weight markers for proteins were from Sigma Aldrich. 
The restriction enzymes and the modification enzymes (calf intestine phosphatase 
and T4 DNA ligase) were supplied by New England Biolabs (NEB) and the molecular 
weight markers for nucleic acids were from NEB and Roche. The Pfu Turbo 
polymerase (2.5 U/μL) was supplied by Stratagene, while Taq DNA polymerase (5 
U/μL) was from NEB. The synthesis of the oligonucleotides was committed at Sigma-
Genosys; pETM11, pETM20, pETM30 and pETM41 E. coli expression plasmids were 
supplied by Novagen; gene constructs cloned in pRSETb were kindly provided by 
prof. Alberto Gulino (Department of Experimental Medicine and Pathology, University 
La Sapienza of Rome), while pET28a/kctd5N-module vector was supplied by prof. 
Steve A. N. Goldstein (Department of Pediatrics and Institute of Molecular Pediatric 
Sciences, University of Chicago). E. coli TOPF’10 strain, used for cloning, was 
supplied by Invitrogen; E. coli BL21CodonPlus(DE3)RIL cells, used for 
overexpression, were supplied by Stratagene. BL21(DE3), BL21(DE3)STAR and 
JM101 strains were supplied by Invitrogen, while Rosetta-GAMI(DE3) were from 
Novagen. Complete Protease Inhibitor Cocktail Tablets were supplied by Roche and 
used as a mixture of protease inhibitors, according to manufacturer’s instruction. 
Ethanol, methanol, isopropilic alcohol and acetic acid were supplied by J.T. Baker. 
TFA was from Fluka. Identity of protein samples and of tryptic digestion products 
were assessed by liquid chromatography mass spectrometry (LC-MS) performed on 
Phenomenex Jupiter C4 and C18 columns, connected to a Thermo Electron 
Corporation mass spectrometer, equipped with an ESI source. Light scattering 
studies were performed on a miniDAWN™ TREOS triple-angle light scattering 
detector, and a Shodex RI-101 refractive index detector, supplied by Wyatt 
Technology Corporation. All size exclusion and affinity chromatography columns 
were connected to AKTA Purifier and FPLC systems (GE-Healthcare). 
 
 
 
 
2.2 Antibiotics 
 
Ampicillin (supplied by Sigma Aldrich as ampicillin sodium salt) and kanamycin 
(supplied by Sigma Aldrich as kanamycin sulphate) were solubilized in deionized 
water at a concentration of 1000X, filter sterilized and stored at –20 °C until use. 
Ampicillin was used at a concentration of 100 µg/mL and kanamycin was used at a 
concentration of 50 µg/mL in both solid and liquid media. Chloramphenicol and 
tetracycline were solubilized in ethanol 96% and used at a concentration of 33 µg/mL 
and 12.5 µg/mL, respectively. 
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2.3 E. coli cells transformation techniques 
 
 
2.3.1 Preparation of E. coli TOPF’10 cells and transformation by electroporation 
 
2.5 mL of an overnight culture of E. coli TOPF’10 cells were inoculated into 250 mL 
of LB medium. The cells were grown up to mid-log phase (0.6 OD600nm) at 37 °C, 
stored on ice for 30 min and then harvested by centrifugation (6000 rpm, 10 min, 4 
°C). The pellet was washed in 250 mL of sterile water. After the second centrifugation 
the cells were washed in 125 mL of sterile water. The third washing was performed in 
5 mL 10% glycerol; the cells were then harvested by centrifugation and the pellet was 
resuspended in 750 μL of 10% glycerol. Aliquots of 1010 cells/mL (40 μL) were mixed 
with 1 μL of the DNA ligase reaction, incubated for 1 min on ice and transferred into 
chilled plastic cuvettes with an electrode gap of 0.2 cm (M-Medical). High voltage 
electroporation (25 μF) was performed with a Bio-Rad Gene Pulser XcellTM at a field 
strength of 2.5 kV/cm and 200 Ohm. A shock pulse was applied to competent cells 
producing pulse length of ~5.0-5.5 ms. Immediately after electroporation cell mixtures 
were diluted to 1 mL with LB medium and incubated for ~1 h at 37 °C under shaking. 
The cells were then plated onto selective solid medium supplemented with 100 
μg/mL ampicillin, 33 μg/mL chloramphenicol or 50 μg/mL kanamycin to isolate the 
recombinant clones. Single clones were inoculated in 5 mL LB medium with the 
same antibiotics and grown over night at 37 °C under shaking. Finally, were 
harvested by centrifugation (13000 rpm, 2 min, 4 °C) and processed to extract 
plasmidic DNA by using the QIAprep Spin Miniprep Kit or the QIAGEN plasmid Maxi 
Kit (both supplied by Qiagen). 
 
 
 
 
2.3.2 Preparation of E. coli competent cells and transformation by heat shock 
 
Single clones of E. coli strains, grown at 37 °C in LB agar, were inoculated into 2.5 
mL of LB medium and incubated overnight at 37 °C on a shaker.  The cells were 
inoculated into 250 mL of LB medium and the culture was grown up to mid-log phase 
(0.6 OD600nm) at 37 °C, stored on ice for 30 min and then harvested by centrifugation 
(6000 rpm, 10 min, 4 °C). The pellet was washed in 125 mL of cold 50 mM CaCl2 and 
stored on ice for 30 min. Successively, the cells were harvested by centrifugation and 
the pellet resuspended in 16 mL of cold 50 mM CaCl2. Aliquots of 200 μL of 
competent cells were mixed with 50 ng of plasmidic DNA and stored on ice for 30 
min. The cells mixtures were transferred at 42 °C for 90 sec, on ice for 2 min (heat 
shock) and then diluted to 1 mL with LB medium. An incubation of 1 h at 37 °C under 
shaking was performed before plating the cells onto selective solid medium 
supplemented with the opportune antibiotics, depending on the strain. 
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2.4 Expression in E. coli of poz/btbkctd11, renkctd11 (“long form”), 
      poz/btbkctd21 and kctd21 
 
2.4.1 Cloning of different constructs 
 
Genes were amplified by PCR from genomic DNA. The amplification was performed 
by using the following couples of primers (the residue numeration is referred to the 
new translation start point): 
 
poz/btb kctd11 (+15 - +116): 
Forward: 5’-CATGCCATGGGCCCCGTGACCCTGAA-3’ 
Reverse: 5’-CCGCTCGAGTTACCTCCAGTTCCCGCAG-3’ 
 
poz/btb kctd11 (+15 – +125): 
Forward: 5’-CATGCCATGGGCCCCGTGACCCTGAA-3’ 
Reverse: 5’-CCGCTCGAGTTATGTGGGTGCAGGGG-3’ 
 
poz/btb kctd11 (+15 - +134): 
Forward: 5’-CATGCCATGGGCCCCGTGACCCTGAA-3’ 
Reverse: 5’-CCGCTCGAGTTAATCTACATCTGCGTGGAGC-3’ 
 
poz kctd11 (+15 - +146): 
Forward: 5’-CATGCCATGGGCCCCGTGACCCTGAA-3’ 
Reverse: 5’-CCGCTCGAGTTAAGAGAAGTGCACCAGGC-3’  
 
poz kctd11 (+1 - +125): 
Forward: 5’-CATGCCATGGCCAAAATTTCTCCTCCTCC-3’ 
Reverse: 5’-CCGCTCGAGTTACCTCCAGTTCCCGCAG-3’ 
 
renkctd11 (+1 - +271): 
Forward: 5’-CATGCCATGGCCAAAATTTCTCCTCCTCC-3’ 
Reverse: 5’-CCGCTCGAGTCAGTGCCGGAC-3’ 
 
pozkctd21 
Forward: 5’-CATGCCATGGCATCCGACCCCATCACGCTG-3’ 
Reverse: 5’-CCGCTCGAGTTAACGCTGGTTCAGTGTGATG-3’ 
 
kctd21 
Forward: 5’-CATGCCATGGCATCCGACCCCATCACGCTG-3’ 
Reverse: 5’-CCGCTCGAGTTACCTGTACCGTATTAATCG-3’ 
 
The forward primers indicated above contained the Nco I restriction site, while the 
reverse primers were designed with the Xho I restriction site (underlined in the 
sequences) and a codon stop at the end of the construct (highlighted in the 
sequences). 
All amplification reactions were performed in a final volume of 50 μL, using 50 ng of 
template DNA. The reaction mixture contained the specific primers (0.25 μM each), 
dNTPs (0.25 mM each) and the Pfu turbo polymerase (5U) with its buffer 1x. 
PCR was performed using an Eppendorf Mastercycler personal apparatus, following 
the procedure indicated below: 
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 Initial denaturation (step 1)  3 min at 95 °C 
 Denaturation (step 2)  1 min at 95 °C 
 Annealing (step 3)   1 min at the convenient temperature for 
each gene amplified 
 Elongation (step 4)   1 min at 72 °C 
for 30 cycles, from step 2. 
 Elongation (step 5)   10 min at 72 °C 
 
 
All amplification products were analyzed by 1% agarose (Euroclone) gel 
electrophoresis performed in TAE buffer (18.6 g/L EDTA, 242 g/L Tris base. Add 
Acetic acid until pH 7.8). PCR products were purified by using the QIAquick PCR 
Purification Kit (Qiagen), and digested with Nco I (20 U/µL) and Xho I (20 U/µL) 
restriction enzymes. Each amplified fragment (1µg) was digested with 4 U of 
restriction enzymes for 3 h at 37 ºC in a buffer containing 50 mM NaCl, 10 mM Tris-
HCl, 10 mM MgCl2, 1 mM DTT pH 7.9 supplemented with BSA 100 μg/mL. Following 
the digestion, each fragment was cloned into the corresponding sites of the pETM11 
expression vector, downstream to the His-tag sequence. To this purpose, the 
expression vector was previously digested with the same restriction enzymes (4 
U/µg), and treated with calf intestine phosphatase (CIP, 10 U) (NEB) for 30 min at 37 
ºC. CIP enzyme (10 U/µL) was then inactivated at 75 °C for 10 min. After digestion, 
PCR amplifications were purified by QIAquick PCR Purification Kit, while the 
NcoI/XhoI pETM11 was purified by QIAquick Gel Extraction Kit (Qiagen). For ligation 
reactions was used a 1:3 molar ratio (vector/insert DNA). The reactions were 
performed using 20 U/µg DNA of the T4 DNA Ligase (400 U/µL), in a final volume of 
10 µL, for 3 h at RT. E. coli TOPF’10 strain was used for cloning. The identity of the 
inserts in the resulting recombinant plasmids was confirmed by DNA sequencing 
(MWG-Biotech). Positive gene constructs were transferred into pETM20 expression 
vector by subcloning. renkctd11 (“long form”) and kctd21 genes were also subcloned in 
pETM30 and pETM41 expression vectors. 
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2.4.2 poz/btb kctd11 gene mutagenesis 
 
Asp69, Arg74, Asn78 and Arg81 residues of POZ/BTBkctd11 domain were mutated in 
alanine by using the QuikChange Site Directed Mutagenesis Kit (Stratagene). The 
primers employed for mutagenesis PCR reaction are reported below: 
 
Forward: 
5’-ACCGGGCTGGCAAGGCCTTCGCGCACATCCTCGCTTTCCTGGCGGG-3’ 
Reverse: 
5’-CCCAGCGCCAGGAAAGCGAGGATGTGCGCGAAGGCCTTGCCAGCCCGGT-3’ 
 
Codons corresponding to the mutated aminoacids are underlined in primers 
sequences. The recombinant construct pETM20/renkctd11 was used as template. The 
PCR reaction was performed, according to the Kit instructions, following the 
procedure indicated below: 
 
 Initial denaturation step (step 1)    1 min at 95 °C 
 Denaturation (step 2)   50 sec at 95 °C 
 Annealing (step 3)    50 sec at 58 °C 
 Elongation (step 4)      1 min at 68 °C 
for 16 cycles from step 2. 
 
XL1-Blue supercompetent cells (supplied by the mutagenesis Kit) were used for the 
transformation of the circular nicked dsDNA, obtained by digesting the methylated, 
non-mutated, parental DNA from PCR with the restriction enzyme DpnI (10 U/µL), for 
2 h at 37 °C. The right insertion of desired mutations was confirmed by DNA 
sequencing. 
 
 
 
 
2.4.3 Expression vector properties 
 
pET plasmids were chosen as they represent a powerful host-vector system for 
cloning and expression of recombinant proteins in E. coli. All of them contain a strong 
promoter from T7 bacteriophage, for chemical induction and overexpression of 
recombinant proteins, a multiple cloning site (MCS) and a TEV protease recognition 
site for cleaving the fusion protein. In particular, pETM11 contains only a 6xHistidine-
tag while to improve the solubility of the gene products pETM20 contains a 
6xHistidine-TrxA fusion tag, pETM30 a 6xHistidine-GST fusion tag, and pETM41 a 
6xHistidine-MBP fusion tag (figure 2.1, 2.2, 2.3 and 2.4). 
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Figure 2.1. Map of expression vector pETM11. 
 
 
 
 
 
 
 
Figure 2.2. Map of expression vector pETM20. 
32 
 
 
 
Figure 2.3. Map of expression vector pETM30. 
 
 
 
 
 
 
 
Figure 2.4. Map of expression vector pETM41. 
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2.4.4 Large-scale expression 
 
After a first screening of small-scale expression cultures, performed using different 
strains, temperatures, IPTG concentration and induction length, recombinant 
constructs were transferred into E. coli strain that assured the best expression level 
in soluble phase. Single clones of E. coli strain, previously transformed with each 
recombinant expression vector and grown at 37 ºC on LB agar containing the 
appropriate antibiotic, were inoculated into 10 mL of LB medium, containing the same 
antibiotic. The overnight cultures were inoculated into 1L of pre-warmed LB medium. 
Cultures were grown at 37 °C under shaking until they reached the mid-log phase 
(0.7/0.8 OD600nm); then, they were induced with the optimal IPTG concentration and 
growth was proceeded at 22° or 37 °C as appropriate. After 3 or 16 h the cells were 
harvested by centrifugation (6000 rpm, 15 min, 4 °C). Cell pellets were resuspended 
in a lysis buffer containing 50 mM Tris/HCl pH 8.0, 150 mM NaCl and protease 
inhibitors. The suspension was sonicated for 10 min, by using a Misonix Sonicator 
3000 apparatus with a micro tip probe and an impulse output of 1.5/2 (=9/12 Watt). 
Bacterial lysates were then centrifuged (16000 rpm, 30 min, 4 °C) and the surnatant 
(soluble fraction) was collected and analyzed by SDS-PAGE to assess the presence 
of recombinant products of interest. 
 
 
2.4.5 Purification of 6xHis-TrxA/MBP/GST tagged proteins 
 
Lysates containing tagged recombinant proteins were purified by affinity 
chromatography onto HisTrap columns connected to an AKTA-FPLC system. Before 
loading the lysate, the resin was extensively washed with water and then equilibrated 
in buffer A (50 mM Tris/HCl pH 8.0, 300 mM NaCl). The lysate was loaded in 
presence of 10 mM imidazole to avoid non-specific binding of E. coli contaminants. 
Flow-through containing all unbound proteins was collected and the resin was 
washed with buffer A; finally His-tagged proteins were eluted with high 
concentrations of imidazole (300 mM). All collected pools (flow-through, washes and 
elutions) were analyzed on SDS–PAGE gels and stained with Coomassie Brilliant 
Blue R-250. Pools of interest were dialyzed to remove imidazole by using 
Spectra/Por membranes with the appropriate MWCO. 
 
 
2.4.6 TEV digestion of tagged proteins 
 
After purification by affinity chromatography, all partner-tagged proteins were 
dialyzed overnight against TEV buffer (50 mM Tris/HCl, pH 7.0/8.0) at 4 °C. TEV 
protease was added to protein substrates, using a molar ratio (protease : substrate) 
of 1 : 50; the cleavage was allowed to proceed 3 h at 30 °C. Cleavage products were 
analyzed by polyacrylamide gel electrophoresis; then, mixture was loaded onto an 
HisTrap column and purification was performed in the same conditions described 
above: protein product of interest was eluted in flow-through, while the fusion partner 
and un-cut complexes were bound to resin and removed with imidazole. 
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2.4.7 Size Exclusion Chromatography 
 
Size exclusion chromatography was performed to purify all recombinant proteins by 
removing aggregates and contaminants. Runs were carried-out at a flow of 1 ml/min 
onto a Superdex-200 and Superdex-75 16/60, Superdex-200 and Superdex-75 
10/300 columns connected to an AKTA Purifier system, in 50 mM Tris/HCl pH 8.0 
and 150 mM NaCl. Molecular weight standards from GE-Healthcare were used to 
calibrate column. Pools of interest were concentrated on Amicon-Ultra membranes 
(Millipore). 
 
 
2.5 PROTEINS ANALYSES 
 
 
2.5.1 Determination of the protein concentration 
 
The concentration of the proteins in solution was determined according to the 
Bradford’s method (Bradford, 1976). The Coomassie Brilliant (Bio-Rad) reagent was 
added to the samples and the absorbance at 595nm was monitored. A solution of 
bovine serum albumin (BSA) was used as standard. Protein concentration was also 
measured by UV spectroscopy, reading the tryptophan absorbance at 280nm, using a 
Jasco V-550 UV-VIS spectrophotometer, in a 1 cm quartz cell. 
 
 
2.5.2 Electrophoretic analysis of proteins (SDS-PAGE) 
 
The electrophoresis on 12%, 15% or 18% polyacrylamide gel in denaturing 
conditions was performed according to Laemmli’s protocol (Laemmli, 1970). The 
samples were denatured at 100°C for 10 min in 1% SDS (Applichem), 5% β-
mercaptoethanol (Sigma), 0.001% bromophenol blue (ICN Biomedicals) and 10% 
glycerol (Applichem). The samples were then loaded on a polyacrylamide gel and the 
electrophoresis was performed in 0.025 M Tris/HCl, 0.2 M glycine pH 8.3 and 0.1% 
SDS, at 30 mA for ~1 h. The proteins were then revealed by Coomassie Brilliant-Blue 
(Applichem) staining; the gel was submerged in the staining solution (0.1% 
Coomassie Brilliant-Blue R250, 25% isopropilic alcohol and 10% acetic acid) for 30 
min with gentle agitation. The gel was washed in a solution containing 30% ethanol 
and 10% acetic acid to remove the excess of Coomassie and then stored in 10% 
acetic acid. For silver staining, the gel was extensively washed in deionised water, 
submerged in the sensibilization solution A (25% ethanol, 0.5 M potassium acetate, 
0.5% glutaraldehyde, 0.3% potassium tetrathionate) and washed again in deionised 
water for 2 times for 10 min each. Then, the gel was equilibrated in solution B (0.2% 
silver nitrate, 0.009% formaldehyde) and stained in solution C (3% potassium 
carbonate, 0.001% sodium thiosulfate, 0.015% formaldehyde), in a dark box, till 
desired contrast was obtained; solution B and C were freshly prepared. Finally, the 
staining reaction was stopped with 10% acetic acid and the gel stored in water. All 
reagents used for silver staining were supplied from Sigma, Del Chimica and Fluka. 
Alternatively, the proteins were transferred by electroblotting from gel to a 
polyvinylidene fluoride (PVDF) membrane as described in the paragraph “Western 
blot analysis”. For native PAGE the samples were loaded on a 10% polyacrylamide 
gel in 0.001% bromophenol blue and 10% glycerol and run in Tris-glycine buffer 
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without SDS. The electrophoresis was performed at 15 mA for 2 h, after a gel pre-run 
of 30 min. Then, the proteins were revealed by Coomassie Brilliant-Blue staining as 
described above. 
 
 
 
 
2.5.3 Western Blot analysis 
 
After gel electrophoresis, proteins were transferred to a polyvinylidene fluoride 
(PVDF) membrane (Immobilon-P, Millipore) in Blotting Buffer (25 mM Tris/HCl pH 
8.0, 190 mM Glycine and 10% methilic alcohol) at 4 °C overnight, using a 25 V 
electric field. The PVDF membrane was submerged in methilic alcohol for 2 min 
before using, to eliminate the hydrophobic properties, washed in H2O for 2 min and 
equilibrated in Blotting Buffer for 5 min. After overnight electro-blotting, membrane 
was stained with Ponceau Red to verify proteins transferring and incubated in the 
blocking solution (5% BSA in PBS buffer, containing 0.05% Tween 20) at room 
temperature for 1 h. It was washed with PBS buffer (137 mM NaCl, 2.7 mM KCl, 10 
mM Na2HPO4, 2 mM KH2PO4 pH 7.4), containing 0.05% Tween 20, and incubated in 
a mouse anti-His monoclonal antibody (Sigma Aldrich) 1:1000 dilution, at room 
temperature for 1 h. Successively, membrane was washed with PBS buffer and 
incubated on a shaker, for 1 h at room temperature, in a 1:1000 dilution of 
horseradish peroxidase-conjugated anti-mouse antibody (Pierce), as the secondary 
antibody. Membrane was finally washed with PBS buffer. The detection of 
immunopositive species by enzyme-linked chemi-luminescence (enhanced chemi-
luminescence: ECL) was performed according to the manufacturer’s instructions 
(Super Signal®West Pico Chemiluminescent Substrate, Pierce), using a ChemiDoc 
XRS apparatus (Bio-Rad). 
 
 
 
 
 
 
 
2.6 Mass spectroscopy and trypsin digestion 
 
LC-MS, using a Phenomenex Jupiter C18 column (4.6 x 250 mm, 5 µm, 300Å), was 
performed to confirm the mass of POZ/BTB. The method developed at 1 mL/min with 
a linear gradient of 0.05% TFA in H2O (buffer A) in 0.05% TFA in CH3CN, from 5% to 
70% for 30 min. 
At the aim to estimate the globular state of POZ/BTB domain, a trypsin digestion was 
performed in 50 mM Tris-HCl pH 7.5 and 20 mM CaCl2, choosing a molar ratio 
trypsin:POZ/BTB of 1:100. The reaction was allowed to proceed at 37 °C and was 
analyzed at different times (30, 45, 60, 90 min) by LC-MS, using a Phenomenex 
Jupiter C4 column (250x2.00 mm, 5 µm, 300 Å) and a method developed at 0.2 
mL/min with a linear gradient of 0.1% aqueous TFA in CH3CN, from 5% to 70% for 
30 min. 
 
 
36 
 
2.7 CD analyses 
 
Far-UV circular dichroism spectra of POZ/BTB were obtained by using a Jasco J-715 
spectropolarimeter, equipped with a PTC-423S/15 Peltier temperature controller, in a 
0.1 mm quartz cell. Spectra were acquired according the following parameters: far 
UV range of 190-260nm, band width of 1nm, response of 8 sec, data pitch of 0.2nm and 
scanning speed of 10 nm/min. Spectra were performed at 20 °C, at a protein 
concentration of 15 µM, in 20 mM phosphate buffer pH 7.0, with and without salts in 
different amounts (NaCl, MgCl2, MgSO4, CoCl2, ZnCl2 and Sodium Citrate, see 
“Results” for details). CD data were expressed as mean residue ellipticity ( ). Spectra 
processing was obtained by using the Spectra Manager software, while the analysis 
of the secondary structure content of the proteins was performed with neural network 
program: CDNN (Bohm, G. et al., 1992). 
POZ/BTB thermal unfolding was performed at 20 µM protein concentration in 20 mM 
phosphate buffer pH 8.0, by using the same Jasco apparatus and the 
temperature/wavelength scan measurement program of the Spectra Manager 
software. The temperature was increased from 20 °C to 100 °C at a rate of 60 °C/h. 
The CD signals were acquired at 1 °C intervals at the indicated wavelength (223nm). 
The conformational behaviour of peptide 49-68 of Cul3 (see results for details) was 
investigated by CD spectroscopy in 10 mM phosphate buffer at pH 7.0 and room 
temperature. CD spectrum was collected on a Jasco J-715 spectropolarimeter from 
185 to 260nm by using a 1 mm quartz cuvette, a scan speed of 10 nm/min, a 
bandwidth of 1.0 nm and a time constant of 8 s. Peptide concentration (5.8 x 10-5 M) 
was determined by monitoring Tyr absorbance at 278nm and using the molar 
extinction coefficient of 2290 M-1 cm-1. CD intensitiy is expressed as mean residue 
ellipticity (deg ×cm2×dmol−1 of amino acid) calculated referring to the total amino acid 
concentration.  
 
 
 
 
2.8 Light scattering (LS) 
 
We used a SEC-LS system consisting of a semi-preparative size exclusion 
chromatography column (Superdex-200 10/30, GEHealthcare) coupled to a light 
scattering detector (miniDAWN TREOS) and a differential refractive index detector 
(Shodex RI-101). 
The Astra (5.3.4 version, Wyatt Technology Corporation) software allowed us to the 
collect, record, and process the scattering data. 
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2.9 ELISA Assays 
 
For ELISA assays, 5 µg/ml streptavidin in phosphate/citrate buffer pH 5.0 was 
incubated over night at 37 °C for coating. First binding was executed with 0.8 µM 
biotinylate peptide 49-68 of Cul3 in PBS 1X for 1 h at room temperature. Second 
binding was performed with different concentrations of His-TrxA/POZ/BTBKCTD11 or 
His/KCTD5 N-module (0.8 µM, 1.5 µM, 3.8 µM, 7.6 µM, 15.6 µM) in PBS 1X. His-
TrxA was employed as negative control in the same concentrations. As blocking 
solution 1% BSA, 0.05% Tween-20 in PBS 1X was used for 1 h at room temperature. 
In order to reveal the occurred interaction mouse anti-His monoclonal antibody was 
incubated in 1:1000 dilution at room temperature for 2 h; then, horseradish 
peroxidase-conjugated anti-mouse antibody (Pierce) was diluted 1:10000 in PBS 1X 
and incubated at room temperature for 1 h. The colorimetric reaction has been 
performed with SIGMA-FAST OPD reagent (Sigma Aldrich), according to the 
manufacturer’s instructions. Finally, a Model 680 Microplate Reader (Bio-Rad) has 
been used for readings at 490nm; data were processed by a Microplate Manager 5.2 
program. 
 
 
2.10 Synthesis of Cul3 peptide 
 
Cul3 peptide encompasses the protein sequence 49-68 (Ac-
NSGLSFEELYRNAYTMVLHK-NH2) of the Cul3 protein. The peptide was acetylated 
and amidated to avoid the electrostatic repulsion between peptide terminal charges 
and putative helix dipole. The peptide was synthesized on solid phase by using 
Fmoc–MBHA rink amide resin to afford a C-terminal amide sequence and standard 
Fmoc (N-9-Fluorenylmethyloxycarbonyl) strategy. The coupling reactions were 
carried out with a ten-fold excess of amino acid using 2-(1H-benzotriazole-1-yl)-
1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) as coupling reagent and 
N,N-diisopropylethylamine (DIEA) in DMF (N,N-dimethylformamide). The 
deprotection step from Fmoc group was performed with 30% piperidine in DMF. 
Before the cleavage from the resin the peptide was acetylated at N-terminus by a 
solution of acetic anhydride/DIEA/ DMF (2.6:4.8:92.6 v/v/v). The crude product was 
cleaved from the resin by treatment with trifluoroacetic acid (TFA)/H2O/1,2-
ethanedithiol (EDT)/triisopropylsilane (TIS) (94:2.5:2.5:1 v/v/v/v) at room temperature 
for 3 h. The resin was then filtered off and Cul3wt peptide was precipitated using 
diethyl ether. 
 
 
2.11 Synthesis of Biotin-Cul3 peptide 
 
The synthesis of Biotin-Cul3 peptide (Biotin-NSGLSFEELYRNAYTMVLHK-NH2) was 
performed as reported above. Before the reaction with TFA the peptidyl-resin was 
treated with a solution of biotin/HATU/DIEA (5:2:2 eq/eq/eq) in DMF to functionalize 
the peptide for the following in vitro studies. The crude product was cleaved from the 
resin as reported for Cul3wt peptide. 
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2.12 Peptide purification and identification 
 
Both peptides were purified by preparative RP-HPLC on a Shimadzu system 
equipped with a Diode Array SPD10AVP using a Phenomenex C12 column (Jupiter 
10 μm; Proteo 90 Å) and a linear gradient of H2O (0.1% TFA)/CH3CN (0.1% TFA) 
from 20 to 70% of CH3CN (0.1% TFA) in 20 min at flow rate of 20 mL/min. Purity and 
identity of the peptides were assesed by analytical RP-HPLC and LC-MS (liquid 
chromatography mass spectometry system). The final yields were 45% and 40 % for 
Cul3 peptide and Biotin-Cul3 peptide, respectively. 
 
 
2.13 Database sequence/structure surveys 
 
Sequence analyses were conducted by using the tools of the server ExPASy 
(http://www.expasy.org/). These analyses were also performed by using data 
available at the POZ/BTB database (http://btb.uhnres.utoronto.ca/index.html) 
developed by Privé and co-workers. The sequence of RENKTCD11 c-DNA was 
retrieved from the site http://www.ensembl.org/ (gene=ENSG00000184542). 
Compute pI/Mw was used for the computation of the theoretical pI and Mw of 
sequences of interest. 
 
2.14 Molecular modelling 
 
A three-dimensional model for POZ/BTB domain of RENKTCD11 was generated by 
using standard molecular modelling techniques. The structure of the Kv4.3 BTB/POZ 
domain determined at 2.1 Å was used as template (PDB code 1NN7). The model, 
generated by using the program Insight II, was energy minimized to remove bad 
contacts and minor stereochemical problems. The overall architecture of the complex 
between POZ/BTBKTCD11 and Cul3 was generated by taking into account the crystal 
structure of the complex between Skp1 and Cul1 (PDB code 1LDK). The model of 
Cul3 was generated from the structure of the closely related Cul4. The larger 
complex formed by POZ/BTBKTCD11 tetramer with Cul3, Rbx1, and E2 was generated 
by considering the crystal structure of the complex Skp1-Cul1–Rbx1 by docking of E2 
on Rbx1 taking into account the architecture of the related complex E2-cCbl. 
 
 
2.15 Crystallization tests 
 
Protein samples of POZ/BTB were concentrated to 10 mg/mL, in 20 mM Tris/HCl pH 
8.0, using Microcon centrifugal filter units with a YM-3 membrane of molecular-weight 
cut-off 3 kDa (Millipore, Bedford, Massachusetts). Protein concentration was 
estimated by the method of Bradford, using BSA as standard (Bradford, 1976). 
Crystallization experiments were carried out at 20 °C using the hanging-drop vapour-
diffusion technique. Initial crystallization conditions were found using commercially 
available crystallization-screening kits (Crystal Screen I and II, Hampton Research, 
Riverside, CA). Drops containing equal volumes (1 μL) of protein and reservoir 
solution were equilibrated against 1 mL of reservoir solution. Several crystal forms 
were obtained, but the best diffracting crystals were grown using a reservoir solution 
containing 1.0 M Li2SO4, 0.4-0.6 M (NH4)2SO4, 0.1 M ADA (pH = 6.0-6.6). Only low-
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resolution data were obtained from these crystals (about 4 Å). They belonged to the 
space group P63
pH, protein concentration and ionic strength were varied in order to improve the 
quality of the crystals. New crystallization conditions were achieved at 20 °C adding 
300 mM NaCl to the protein buffer and using a reservoir solution consisting of 1.0 M 
Li2SO4, 0.5 M (NH4)2SO4, 0.1 M tri-sodium citrate (pH = 5.6). This last crystallization 
experiment was carried out using the sitting-drop vapour-diffusion method, by 
equilibrating 0.2 μL drops against 100 μL of reservoir solution. 
 
 
2.16 Expression of 15N-labelled recombinant POZ/BTBKCTD11 for NMR 
studies 
 
A single clone of JM101 strain was cultured for 3 h at 37 °C in 5 ml of LB medium 
without antibiotics. The cells were then inoculated in M9 medium (see composition in 
tables 1 and 2), containing 15NH4Cl (1 g/l) as the sole nitrogen source, and grown 
overnight at 37 °C. The harvested cells were lysed with 37% HCl at 95 °C for 8 h, to 
obtain a mixture of single 15N labeled amino acids; this mixture was used to enrich 
M9 medium for the expression of POZ/BTBKCTD11 in E. coli BL21CodonPlus(DE3)RIL 
strain previously transformed with pETM20/poz/btbkctd11 recombinant expression 
vector. The expression and protein purification were performed as described for the 
unlabeled protein. 
 
 
 
 
M9 salt solution 10X 100 ml 
1 M MgSO4 1 ml 
10 mM CaCl2 10 ml 
1 % thiamine 1 ml 
20% glucose 10 ml 
ddH2O 878 ml 
Total volume 1 liter 
Table 1: M9 medium composition. 
 
 
Na2HPO4 6 g 
KH2PO4 3 g 
NaCl 0.5 g 
15NH4Cl 1 g 
ddH2O to 100 ml 
Total volume 100 ml 
Table 2: M9 salt solution 10X composition.  
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2.16.1 NMR Spectroscopy - Peptide-protein interactions 
 
NMR measurements were performed on a Varian Unity Inova 600 MHz spectrometer 
equipped with a cold-probe, using either unlabeled (500 M) or uniformly 15N labeled 
(400 M) POZ/BTB in 50 mM Tris/HCl and 150 mM NaCl, pH 8.0. Peptide-protein 
interactions were performed using the peptide 49-68 Cul3 and were monitored by 
identifying perturbations in 2D 1H, 15N  HSQC spectra. 15N-POZ/BTBKCTD11 was 
titrated increasing peptide concentrations. 2D 1H, 15N  HSQC spectra were acquired 
with 32 transients per t1 value. Pre-saturation of water was employed during a 
recycle delay of 1.5 s. 1K complex points were acquired in t2, with an acquisition time 
of 102.5 ms, while 128 complex points were acquired in t1 with an acquisition time of 
64 ms. To determine the per residue chemical shift perturbation upon binding and 
account for differences in spectral widths between 15N and 1H resonances, weighted 
average chemical shift differences, av(HN), were calculated for the amide 15N and 
1H resonances, using equation: 
 
 
av(HN) = H2 + ( N/2)2
½ 
 
 
H and N represent the differences between free and bound chemical shifts. 
Spectra of the unlabeled POZ/BTB/peptide complex were recorded with 2048 scans 
and selective saturation of the protein resonances at 12 ppm and 3 ppm. Time 
dependence of the saturation transfer was investigated using an optimized saturation 
times ranging from 0.2 to 4.0 s. STD NMR spectra were acquired using a series of 
equally spaced 50 ms Gaussian-shaped pulses for selective saturation, with 1 ms 
delay between the pulses. Subtraction of the protein FID resonance was performed 
by phase cycling. 
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2.17 Expression in yeast of RENKCTD11 (“short form”) 
 
renKCTD11 gene was first cloned into pGEM-T Easy vector (Promega) and then 
recovered from it by digesting with Nsi I and Pst I restriction enzymes; finally the 
insert was subcloned in the expression vector YEp352 (Yeast Expression plasmid) 
(figure 2.5), previously digested with the restriction enzymes Pst I and Nar I. 
renKCTD11 was cloned in frame with a strong non-regulated promoter (PGK promoter), 
that allows a continuous gene expression. Moreover, a signal sequence that vehicles 
the expressed protein in the extracellular medium is placed upstream the insert. The 
recombinant vector YEp/renKCTD11 was used to transform a strain of Saccharomyces 
cerevisiae (gently provided by prof. Giovanni Sannia, Department of Biological 
Sciences, University Federico II of Naples). 1 ml of 0.1 M lithium acetate has been 
added to the cells of S. cerevisiae for 5 min at 30 °C. The sample was centrifuged, 
the supernatant removed and the pellet resuspended in 0.35 ml of PLATE (40% PEG 
4000, 0.1 M lithium acetate, 0.1 M Tris/HCl pH 7.5, 1 mM EDTA), 100 µg of DNA of 
salmon sperm and 5 µg of plasmid YEp/renKCTD11. The sample was incubated for 20 
min at 42 °C and then centrifuged. The supernatant was discarded and the pellet 
resuspended in 0.2 ml of sterile H2O. The transformed cells were plated on selective 
medium (6.7 g/l base nitrogenous, 5 g/l casein, 2% glucose, 30 mg/l adenine, 40 mg/l 
tryptophan, 50 mM succinate buffer pH 5.3). The plates were incubated at 30 °C for 4 
days. A colony of S. cerevisiae transformed with the vector YEp/renKCTD11 was grown 
in 10 ml of selective medium, with a shaking of 150 rpm, at 30 °C for three days. The 
culture was diluted in 50 ml of selective medium, and grown until an optical density of 
0.5 (600nm). 2 ml of culture were collected every 24 h for 7 days and cells were 
separated from the extracellular medium. The extracellular media was concentrated; 
RENKCTD11 protein expression was verified through SDS-PAGE analysis followed by 
silver staining and also by Western Blot, using the α-RENKCTD11 antibody. 
 
 
 
Figure 2.5. Map of expression vector Yep352. 
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2.18 Expression in mammalian cells 
 
2.18.1 Cloning of renKCTD11 in pBOS 
 
Cloning of renKCTD11 (“short” and “long form”) in pBOS eukaryotic vector was based 
on a three steps PCR strategy. As a first step, a “leader sequence” was amplified 
from the pBOS/apo-AI recombinant vector, already available in our lab, by using the 
following couples of primers: 
 
Short form 
Forward1: 5’-CCGGAATTCATGAAAGCTGGTGTG-3’ 
Reverse1: 5’-CATGGCCCCCAGCATAGCCTGGCTCCCCG-3’ 
 
Long form 
Forward1: 5’-CCGGAATTCATGAAAGCTGCTGCGGTGCTG-3’ 
Reverse1: 5’-TCACGGGGCCAGCCTGGCTCCCCGTC-3’ 
 
In the second PCR, renKCTD11 was amplified from pRSET/renKCTD11 by using the 
following couples of primers: 
 
Short form 
Forward2: 5’-CGGGGAGCCAGGCTATGCTGGGGGCCATG-3’ 
Reverse2: 5’-CCGGAATTCTCAGTGGCGCACAAAGC-3’ 
 
Long form 
Forward2: 5’-GAGCCAGGCTGGCCCCGTGACCCTGA-3’ 
Reverse2: 5’-CCGGAATTCTCAGTGCCGCACAAAGC-3’ 
 
Forward1 and Reverse2 primers contained the EcoR I restriction site (underlined in 
the sequences), while Reverse1 primer contained the 5’-terminal portion of renKCTD11 
(in red), and Forward2 the 3’-terminal portion of “leader sequence” (in blue). 
First and second PCR products (with overlapping ends) were used as templates in 
the third PCR performed with Forward1 and Reverse2 primers; in this way, the 
“leader sequence” was inserted upstream renKCTD11 gene. After a digestion with EcoR 
I restriction enzyme, the final product has been purified and cloned into pBOS 
mammalian expression vector, previously digested with the same enzyme. This 
vector contains the strong EF1α promoter, in frame with the insertion site, and the 
SV40 replication origin. PCR, digestion and ligation reactions were performed in the 
same conditions described above (see paragraph “Cloning”). Identity of the insert 
was confirmed by DNA sequencing. 
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2.18.2 Cell culture and transfection 
 
293T and CHO KI cells were cultured in DMEM supplemented with 50 units/ml 
penicillin, 50 µg/ml streptomycin, 4 mM L-glutamine (Euroclone), and 10% FBS 
(HyClone Perbio). They were splitted every 3-4 days with 1:10 to 1:20 dilution and 
cultured at 37 °C, in 5% CO2. Transient transfection was performed at a confluence 
of 60-70% in OptiMEM medium (Invitrogen) with 3 µg of recombinant plasmidic DNA 
(pBOS/renKCTD11), by using Lipofectamine Reagent from Invitrogen, according to 
manufacturer’s instructions. After 5 h of incubation, the medium was changed with 
DMEM supplemented with 0,5% FBS and 4 mM L-glutamine. After 24 h the 
proteasome inhibitor MG132 (30 µM, from Calbiochem) was added for 6 h. Then, 
medium was harvested and centrifuged, protease inhibitors were added to surnatant, 
and the sample analyzed by Western Blotting. For stable transfection, cells were co-
transfected with 3 µg of pBOS/renKCTD11 and 300 ng of pSV2neo (Clontech), 
containing the gene for neomycin resistance. After 5 h of incubation, the medium was 
changed with DMEM supplemented with 0,5 % FBS, 4 mM L-glutamine and 500 
µg/ml G418 (Euroclone). Stably transfected clones were isolated, amplified, and then 
analyzed by Western Blotting, using for the detection a monoclonal anti-RENKCTD11 
antibody, kindly provided by prof. A. Gulino’s co-workers. As negative control, not 
transfected cells were used. 
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3 RESULTS 
 
3.1 The protein RENKTCD11 
 
The protein RENKTCD11 is an important regulator of the Hedgehog pathway and is 
involved in the development of medulloblastoma. RENKTCD11 is a 232 aminoacids 
protein detected in several mammalian species. Although its role in the development 
of the disease has been clearly demonstrated, the biological action of the protein has 
not been fully characterized yet. The limited similarity of RENKTCD11 with proteins with 
known sequence/structure also prevents straightforward prediction of its function. 
Sequence similarity searches carried out for RENKTCD11 indicate that three distinct 
regions presumably compose the protein: N-terminal domain (POZ/BTB), residues 1-
80, a putative central domain, residues 81-180 and a putative COOH domain, 
residues 181-232. In collaboration with the group of prof. Alberto Gulino the 
constructs for RENKCTD11 full length and the deleted forms POZ, Cter were cloned 
in the expression vector pRSET. Tests of expression have been conducted in several 
strains of E. coli, varying temperature, concentration of IPTG and time of induction. 
The recombinant proteins formed inclusion bodies under all the analyzed conditions. 
Various protocols of refolding have been used, then, to recover the recombinant 
proteins from the inclusion bodies, but despite the numerous efforts the final yield 
has been low. Our attention has been focused on the protein full length and on the 
possibility that post-translational modifications could have for the correct folding. 
RENKCTD11 has been expressed, therefore, in mammalian and yeast cells. 
 
 
 
3.2 Expression of RENKCTD11 in yeast 
 
In order to express RENKCTD11 in yeast, the corresponding gene, cut with the 
restriction enzymes Nsi I and Pst I, was sub-cloned in the expression vector YEp352 
previously cutted with the restriction enzymes Pst I and Nar I. The recombinant 
vector, YEpRENKCTD11, was used to transform a strain of Saccharomyces cerevisiae. 
S. cerevisiae was grown in selective medium and the recombinant protein, 
RENKCTD11, was expressed in the extracellular medium. 2 ml of culture were collected 
every 24 h for 7 days and the cells were separated from the extracellular medium. 
The extracellular media were concentrated up to 0.1 ml. RENKCTD11 expression was 
verified by SDS-PAGE analysis followed by silver staining. The SDS-PAGE analysis 
highlights the presence of a protein band corresponding to a molecular weight of 25 
kDa, expected for RENKCTD11 in the medium of S. cerevisiae cells transformed with 
the vector YEpRENKCTD11. In order to improve the expression of RENKCTD11, we have 
prepared a sample of 10 ml (figure 3.1). Finally Western Blot analysis confirmed the 
presence of a protein in the extracellular medium derived from transformed cells, 
which is absent in the medium of wild-type cells. The final yield, nevertheless, has 
been very low and unsuitable structural characterization (figure 3.2). 
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Figure 3.1. SDS-PAGE analysis of expression of RENKCTD11 in yeast. Lane 1 shows extracellular 
medium of S. cerevisiae wild-type after 96 h, in lane 2 low-range protein marker (Sigma) and lane 3 
and 4 show extracellular medium of the recombinant S. cerevisiae after 72 and 96 h. 
 
 
 
 
 
 
 
 
Figure 3.2. Western blot analysis of RENKCTD11 expression in yeast cells. In lane 1 extracellular 
medium of S. cerevisiae wild-type after 96 h; in lane 2 extracellular medium of recombinant S. 
cerevisiae after 96 h. 
 
 
 
 
 
3.3 Expression of RENKCTD11 in mammalian cells 
In order to express RENKCTD11 in mammalian cells the recombinant vector 
pBOS/renkctd11 has been used thus to obtain the protein secreted into culture 
medium. CHO K1 cells were transfected with this vector and treated with and without 
the proteasome inhibitor MG132. The media were analyzed by western blot, using, 
for the detection, a monoclonal anti-RENKCTD11 antibody, kindly provided by A. 
Gulino’s co-workers. Only in the samples treated with the proteasome inhibitor a 
chemiluminescent signal in correspondence of RENKCTD11 expected molecular weight 
(~27 KDa) has been detected (data not shown). This suggests that, soon after the 
expression, the recombinant protein was targeted to the degradation by host defence 
mechanisms, preventing its secretion outside the cell. Anyway, even in presence of 
MG132, RENKCTD11 expression level was not sufficient for subsequent purification. 
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3.4 RENKCTD11 “long form” 
 
Since the early characterizations of the protein, it was shown that the sequence N-
terminus of RENKTCD11 exhibits significant similarities with the POZ/BTB domains. 
Analyses of sequence databases did not reveal any significant similarity for the rest 
of the protein. POZ/BTB are widespread and well-characterized domains detected in 
several systems involved in a variety of biological processes. For several members of 
this family, three-dimensional structures are available. Recent comparative analyses 
have clearly indicated that the structures of these domains are characterized by 
variations on a conserved structural theme. Indeed in every structure a module 
formed by a three-stranded β-sheet and five α helixes is present. Alignments of 
POZ/BTB sequences of members with unknown structures suggest also that these 
elements are strictly conserved among the proteins of the family. Intriguingly, the 
POZ/BTB domain of RENKTCD11 is peculiar in this general framework. According to 
the available sequences of RENKTCD11 isolated from different sources, only a portion 
of the conserved core of the POZ/BTB domain is present in these proteins. 
Sequence alignments show that the part of the domain corresponding to the β-
strands B1 and B2 and the to the α-helix A1 is absent (figure 3.3). This unusual 
scenario prompted us to check the possibility of an alternative initiation point of 
RENKTCD11 mRNA translation. The analysis of the RENKTCD11 cDNA sequence clearly 
indicates that the entire POZ/BTB conserved core could be generated simply using 
an alternative starting point for the traduction of the protein. Indeed, the DNA triplets 
preceding those corresponding to the putative first residue of the reported sequence 
(Met1) encode for residues that are very similar to those observed in the other 
POZ/BTB domains. The building of the entire POZ/BTB requires 24 extra aminoacids 
at the N-terminal side of the protein (figure 3.4 and 3.5). In this scenario, subsequent 
research activities followed two different directions aimed to characterize the two 
alternative forms of RENKTCD11 POZ/BTB domain and evaluate the possibility of an 
additional initiation point of translation by in vitro experiments. All these important 
findings have been confirmed by in vitro experiments performed by Alberto Gulino’s 
group. They mutated each valine and isoleucine residue placed upstream the 
methionine +1, in order to identify the real start point of translation. The results of 
these experiments identified the isoleucine -39 as translation start point for the 
RENKCTD11 (figure 3.6); consequently the complete protein sequence of RENKTCD11, 
271 aminoacids, has been redefined. Further research activities were focused to 
characterize the new “long” form of RENKTCD11 and its POZ/BTB domain, individuated 
as aminoacid residues +15 - +116. 
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Figure 3.3. Alignments of BTB/POZ domains reported in sequences databases. The sequence of the 
translated REN
KTCD11
 c-DNA sequence was used in the query. The methionine that is the starting 
residue in the short REN
KTCD11
 form is the residue 101 in this sequence. With the exception of the 
human, mouse and bovine REN
KTCD11
 (shown in green) sequences, all others present an extra region 
at the N-terminal side, which likely corresponds to the structural elements B1, B2 and A1 of the 
domain core. 
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GFLCPDTTSPSTTKVAGVSPKPYWVCSTCASNPANLTASTQFCTHPGSSAFSFLSVSPVL
PKISPPPVPSSPPSFGGPVTLNVGGTLYSTTLETLTRFPDSMLGAMFRAGTPMPPNLNSQ
GGGHYFIDRDGKAFRHILNFLRLGRLDLPRGYGETALLRAEADFYQIRPLLDALRELEAS
QGTPAPTAALLHADVDVSPRLVHFSARRGPHHYELSSVQVDTFRANLFCTDSECLGALRA
RFGVASGDRAEGSPHFHLEWAPRPVELPEVEYGRLGLQPLWTGGPGERREVVGTPSFLEE
VLRVALEHGFRLDSVFPDPEDLLNSRSLRFVRH  
 
Figure 3.4. Building of the entire POZ/BTB with addition of 24 extra aminoacids at the N-terminal side 
of the protein, corresponding to the β-strands B1 and B2 and to the α-helix A1. 
 
 
 
Figure 3.5. Model of the "long" form of POZ/BTB, in red are represented the β-strands B1 and B2 and 
the α-helix A1 added. 
 
 
 
Figure 3.6. Isoleucine placed 39 aminoacids upstream of methionine +1 as new translation start point 
of REN
KCTD11
. 
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3.5 Expression of RENKCTD11 “long form” in E. coli  
 
The “long” form of RENKCTD11 with isoleucine as new translation start point was 
cloned in pETM41 and expressed in E. coli as a fusion protein with the Maltose 
Binding Protein (MBP). The strain BL21(DE3)STAR was chosen for the expression 
and the expression was conducted at 22 °C for 16 h. The soluble fusion protein MBP-
RENKCTD11 was purified by affinity chromatography exploiting the presence of a tail of 
histidines situated at N-terminus of MPB. The consequent molecular exclusion 
chromatography (Superdex 200 10/30) combined with light scattering analysis 
allowed us to highlight a tetrameric organization of the recombinant protein and a 
hydrodynamic radius of 9.2 nm (figure 3.7). RENKCTD11 was separated from the fusion 
partner through proteolysis conducted at 30 °C for 3 h in the presence of TEV 
protease. The protein, without partner, aggregates in solution by forming complexes 
of high molecular weight that did not allow us to continue the structural analysis of 
the protein. 
 
 
 
 
 
Figure 3.7. Rh conformation plot obtained by light scattering analysis of MBP-REN
KCTD11
: 
hydrodynamic radius versus molecular mass plot. 
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3.6 Expression of RENKCTD11 “long form” in mammalian cells 
 
RENKCTD11 without fusion partner is unstable, probably because the recombinant 
protein isolated from E. coli lacks of eventual post-translational modifications, which 
could be required for protein stability. Therefore, a new mammalian recombinant 
construct was designed, inserting the long sequence of RENKCTD11 into pBOS, in 
frame with the leader sequence for outside secretion. CHO KI cells have been stably 
transfected with it and the culture medium was collected after 24 and 48 h from 
transfection. Western blot analysis of a selected stable clone has shown a significant 
expression level of RENKCTD11 in the sample collected after 24 h (figure 3.8). This 
result has been obtained without proteosome inhibitor suggesting a higher stability of 
the protein expressed and it was encouraging for next characterization phases. At 
present, an expression large-scaling is in progress. 
 
 
 
 
Figure 3.8. Western blot analysis of REN
KCTD11 
expression in CHO KI cells. Lane 1: prestained Mw 
markers. Lane 2 and 4: culture medium of untransfected cells, as negative control. Lane 3 and 5: 
culture medium of stable clone 6 at 24 and 48 h from transfection. 
 
3.7 Expression of POZ/BTBKCTD11 domain in E. coli 
 
The “long” form of POZ/BTB (residues +15 - +116) has been cloned in pETM20 and 
expressed in strain BL21(DE3)STAR of E. coli. The induction was performed with 0.5 
mM IPTG, added to cells at an optical density of 0.8 OD600nm, for 16 h at 22 °C. This 
strategy permits to obtain the domain as fusion protein with Thioredoxin-A (Trx-A). 
The POZ/BTB domain has been purified to homogeneity by three purification steps 
utilizing its nickel affinity and molecular weight properties. The extract was loaded on 
a his-trap column equilibrated with 50 mM Tris⁄HCl pH 8.0, 300 mM NaCl and 10 mM 
imidazole (buffer A). The fusion protein, then, was eluted with the same buffer A 
supplemented with 250 mM imidazole (figure 3.9). The active fractions were pooled 
and dialyzed against 20 mM Tris⁄HCl pH 8.0, 100 mM NaCl, 1 mM DTT. The Trx-A 
has been separated by the domain POZ/BTB through a proteolysis conducted for 3 h 
at 30 °C with the protease TEV. The optimal conditions for TEV digestion were 
achieved at a protease/protein molar ratio of 1:50. The next affinity chromatography 
enabled to remove the Trx-A and the protease TEV from interest protein. The 
concentrated sample was applied onto the HiLoad Superdex 75 column connected to 
an AKTA FPLC system and eluted with 50 mM Tris⁄HCl pH 8.0, 200 mM NaCl at a 
ﬂow rate of 1 mL/min. After molecular exclusion chromatography, only one protein 
band was observed on SDS-PAGE analysis (figure 3.10). The protein yield from 1L 
of cultures was about 40 mg of the recombinant protein. The production of significant 
amounts of the domain in a pure and homogeneous form allowed a detailed 
characterization of its properties in solution. Analytical gel-filtration chromatography 
clearly indicates that the protein has a tetrameric organization with a molecular 
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weight of about 55 kDa. No significant peaks are found at the elution time expected 
for the monomeric form. 
 
 
 
 
 
Figure 3.9. SDS-PAGE analysis: purification of Trx-A-POZ/BTB by nickel affinity chromatography. 
Lane 1 shows cytosolic extract, lane 2 flow throught, lane 3-4-5-6 elutions with increasing 
concentrations of imidazole, lane 7 low range protein marker (sigma). 
 
 
 
 
 
 
 
 
Figure 3.10. Chromatographic elution profile of POZ/BTB
KCTD11
 obtained by size exclusion 
chromatography with a S75 16/60 column.  
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3.8 Biochemical characterization of POZ/BTBKCTD11 domain  
 
Accurate information about the quaternary structure of POZ/BTB domain was 
obtained combining molecular exclusion chromatography (Superdex 75 10/30) with 
light scattering analysis. The report provides a molecular weight of 56 KDa, 
comparable to that expected for a tetrameric organization of POZ/BTB, and a 
hydrodynamic radius of domain, 4.5 nm (figure 3.11). The value of radius indicates a 
globular form for POZ/BTB in agreement with data in silico. 
 
 
 
Figure 3.11. Rh conformation plot derived from light scattering analysis of POZ/BTB: hydrodynamic 
radius versus molecular mass plot. 
 
The structural integrity of the POZ/BTB domain was valued by native PAGE. The 
sample presents a single protein band showing the homogeneity of the sample 
(figure 3.12). 
 
 
Figure 3.12. Native PAGE analysis of POZ/BTB
KCTD11
. 
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The protein identity was assessed by liquid chromatography mass spectrometry. The 
molecular weight calculated from experimental data was in agreement with 
theoretical one (figure 3.13). BTB/POZ, then, was subjected to a trypsin digestion, in 
order to estimate the globular state of the protein. Trypsin was added to the mix in a 
molar ratio enzyme: BTB/POZ of 1:100. The reaction was analyzed by LC-MS at 
different times (30 min, 45 min, 1 h, 2 h) and showed a stable conformation of the 
protein that was not drastically digested by trypsin, as attended for a compact 
domain. 
Further, POZ/BTB was analyzed by far-UV CD spectroscopy. CD spectra, recorded 
in the 190-260nm region, clearly demonstrated that the domain exhibits an ordered 
structure. The location of the maximum and the minima in the spectrum suggests that 
the protein contains both α and β structural elements (figure 3.14). The thermal 
stability of the protein was investigated by following the CD signal at 223nm in the 
temperature range 20-100 °C. As shown in figure 3.15 a transition is observed at 54 
°C and its thermal denaturation is irreversible. POZ/BTB after the thermal 
denaturation is unstable because it precipitates. Finally, the sample was subjected to 
numerous tests of crystallization in collaboration with G. De Simone IBB CNR, but in 
all conditions carried out POZ/BTB produced small crystals (figure 3.16).  
 
 
 
 
Figure 3.13. LC-MS analysis of the POZ/BTB
KCTD11
; a: ESI spectrum; b: deconvolution analysis of 
POZ/BTB
KCTD11 
charged states corresponds to a mass of 12426.4 Da that is in agreement with the 
theoretical one. 
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Figure 3.14. Far-UV spectrum POZ/BTB
KCTD11
 domain. 
 
 
 
 
 
 
 
Figure 3.15. Thermal denaturation of POZ/BTB
KCTD11
: CD signal was followed at 223nm in the 
temperature range 20-100 °C. 
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Figure 3.16. Micro-crystals of BTB/POZ obtained at 20 °C using the hanging-drop vapour-diffusion 
technique. 
 
3.9 Design of construct POZ/BTB +15 – +125 
 
In order to improve the size and the quality of POZ/BTB crystals, it was decided to 
reconsider the extension of the domain on the basis of structural predictions: the C-
terminal domain was extended with 9 residues downstream of the last putative alpha 
helix. The new construct, POZ/BTB +15 - +125 (figure 3.17), was cloned and 
expressed in E. coli using the same conditions described above. 
 
 
 
Figure 3.17. Construct of POZ/BTB +15 - +125; in purple is reported the sequence (9 aminoacids) 
added at C-terminal of domain. 
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In order to identify the optimal conditions for the stabilization of the tetrameric form, 
and hence its crystallization CD thermal denaturation in the presence of different 
salts, including sodium citrate, sodium chloride and magnesium chloride were carried 
out. All these salts were able to stabilize the domain, in particular increasing the 
concentration of sodium chloride until 400 mM an increase in melting temperature of 
5 °C (54 °C to 59 °C) was observed (figure 3.18). This information has been used to 
develop new tests of crystallization from which were obtained crystals bigger than 
those previously analyzed. Unfortunately, these crystals diffracted a 4.0 Å of 
resolution, not enough to solve the structure (figure 3.19). 
 
 
 
 
Figure 3.18. Far-UV CD spectra of BTB/POZ in the presence of increasing concentrations of NaCl. 
 
 
 
 
 
 
 
Figure 3.19. Crystals of BTB/POZ obtained at 20 °C using the hanging-drop vapour-diffusion 
technique. 
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3.10 New constructs of POZ/BTBKCTD11 domain 
 
In order to add further structural motifs and to facilitate the correct folding of the 
domain, three new POZ/BTB constructs based on sequence alignments and 
secondary structure predictions were designed. In particular, two constructs were 
designed with further 9 and 21 residues at C-terminal in order to introduce two 
additional alpha helixes present in Privè’ s model; while the third construct was 
prolonged at N-terminus until translation start residue (figure 3.20). The three 
constructs were cloned in pETM20 vector and expressed in E. coli under the same 
conditions used to express POZ/BTB (+15 - +125). These changes haven’t obtained 
the expected improvements; in fact the new constructs were less stable. The 
construct with 9 additional residues at the C-terminus forms crystals of different 
morphology compared to those obtained by previous POZ/BTB domain, but these 
crystals do not provide a diffraction pattern with a better resolution (figure 3.21). 
 
 
 
 
 
Figure 3.20. Design of three new constructs of POZ/BTB. In cyan the additional aminoacids in the 
construct +1 - +125, in purple and in green the additional aminoacids in the constructs +15 - +134 and 
+15 - +146 respectively. 
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Figure 3.21. Crystals of BTB/POZ +15 - +134 obtained at 20 °C using the hanging-drop vapour-
diffusion technique (4.0 Å resolution). 
 
3.11 Design of POZ/BTB mutants by molecular modelling 
 
The BTB/POZ tetramerization domains of the potassium channels Kv4 are the 
proteins with known 3D structure most closely related to the N-terminal region of 
RENKTCD11. This observation suggests that using comparative molecular modeling 
techniques may generate reliable models of BTB/POZ domain of RENKTCD11. The 
analysis of the 3D model generated POZ/BTB of RENKTCD11 suggests analogies and 
differences with the Kv4 model used as a template. The crystal structure of the Kv4 
fragment, which spans from residue 46 to 146, shows that four independent chains of 
the protein, each characterized by a structure, form a tetramer (figure 3.22). Two 
different types of interactions stabilize the tetramer interface. The most important 
ones are mediated by a zinc ion that is coordinated by cysteine and histidine 
residues belonging to different subunits. In particular, Cys 132, Cys 133, and His 105 
of one subunit and Cys 121 of an adjacent chain coordinate the zinc ion. Further 
stability to the POZ/BTB tetramer of Kv4 is provided by hydrogen bonding and 
electrostatic interactions among residues located at the inter-subunit interface (Figure 
3.23 a and 3.23 b). It is worth noticing that residues that participate in the 
coordination of the zinc ions in Kv4 POZ/BTB domain are absent in RENKTCD11 
sequence. On the other hand, most of the residues involved in the other interactions, 
essentially electrostatic, are present in RENKTCD11 sequence. In particular, conserved 
residues are: Arg93 (Kv4 sequence numbering), Asp 88, Asn 97, and Arg 100. It is 
also important to mention that, although Glu 110 is replaced by a Tyr residue, a 
nearby Glu may play the role of Glu 110. A similar situation is observed for the 
partner of Arg100, i.e. Glu 117, which is replaced by a Lys residue in RENKTCD11 
sequence (figure 3.24). In conclusion the present analysis clearly indicates that the 
stability of the RENKTCD11 POZ/BTB tetramer essentially relies on electrostatic 
interactions at the intersubunit interface. So a mutant of POZ/BTB domain has been 
designed in which four residues, Asp 69, Arg74, Asn78, Arg 81 were mutated into 
alanine in order to alter the interface of interaction between molecules and to 
destabilize the tetramer. 
The mutant POZ/BTB (construct +15 – +116) was cloned in pETM20 and expressed 
in the same conditions of wild-type domain. The mutant POZ/BTB aggregates in 
solution, as demonstrated from the analysis conducted on molecular exclusion 
chromatography. The results obtained with the mutant POZ/BTB allowed us to 
identify residues potentially involved in the formation of the tetramer and to confirm 
the instability in solution of the POZ/BTB as monomer. 
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Figure 3.22. Tetrameric structure of the Kv4 POZ/BTB domain. The zinc ions located at the inter-
subunit interface are colored in magenta. 
 
 
 
   
 
Figure 3.23. Interactions that stabilize the tetramer interface of Kv4 POZ/BTB domain. a: Coordination 
of the zinc ions located at the inter-subunit interface. b: Electrostatic interactions located at the inter-
subunit interface. 
 
 
 
 
Figure 3.24. Sequence alignment of the POZ/BTB domain of REN
KCTD11
 and the potassium channel 
Kv4. Residues of REN
KCTD11
 sequence that might participate to the inter-subunit interface of the 
putative protein tetramer are colored in red. 
 
 
a b 
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3.12 KCTD21 
 
After a careful analysis of sequence alignments, our attention was focused on a new 
"open reading frame", kctd21, which presents 42% identity with kctd11 (figure 3.25). 
The gene kctd21 is located on chromosome 11, which in some rare cases of 
medulloblastoma shows events of deletion and encodes a putative protein of 260 
amino acids. The full-length form and the domain POZ/BTB were cloned and 
expressed in E. coli in order to obtain structural information that could be extended to 
RENKCTD11. Despite having tested several fusion constructs and numerous conditions 
of induction, KCTD21 was unstable in solution and consequently not characterized. 
With regard to the POZ/BTB of KCTD21, it has been cloned in pETM20 and has 
been expressed at 22 °C for 16 h in BL21(DE3)STAR as fusion protein with Trx-A. 
The analysis of the chromatographic profile of molecular exclusion chromatography 
has provided us data showing that POZ/BTB of KCTD21 is organized in a tetrameric 
structure, but differently from POZ/BTB of RENKCTD11 it is highly unstable in solution, 
so it was impossible to proceed with the crystallographic investigations (figure 3.26). 
 
 
 
 
 
Figure 3.25. Sequence alignment of KCTD21 and REN
KCTD11
. Residues that participate to the inter-
subunit interface of the putative protein tetramer are conserved and are colored in red. 
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Figure 3.26. Molecular size exclusion chromatographic elution profile of POZ/BTB of KCTD21. 
 
 
3.13 Model of interaction between POZ/BTBKCTD11 and Cul3 
 
It is known in literature that members of the family Cul3 bind proteins containing 
POZ/BTB domain. Our hypothesis is that RENKCTD11 may be involved in large 
complexes denoted as ubiquitin-protein ligases (E3) and that interacts with Cul3 by 
its POZ/BTB domains. We investigated the possibility to build 3D models of these 
complexes. All structures of POZ/BTB-Cul3 complexes hitherto reported contain a 
single POZ/BTB domain interaction with a single Cul3 molecule. We initially 
considered the structure of the complex between Cul1 and Skp1 to build a one to one 
complex of RENKTCD11 POZ/BTB–Cul3. The POZ/BTB domain interacts with its 
partner essentially through the β-strand B3 of the β-sheet and the helix A2. It is worth 
mentioning that these fragments are present in the sequence of RENKTCD11 short 
form (figure 3.27). This may account for the observed functionality of this form in the 
regulation of the Hedgehog pathway in cells over expressing the protein. Although 
the efficient binding of POZ/BTB to Cul3 likely requires the presence of the missing 
parts, the presence in the short form sequence of these regions allows the anchoring 
of the protein to the Cul3 when RENKTCD11 is over-expressed. The experimental 
evidence that RENKTCD11 POZ/BTB forms stable tetramer in solution prompted us to 
check the possibility to generate larger POZ/BTB-Cul3 complexes. As shown in 
figure 3.28, a convincing complex between POZ/BTB of RENKTCD11 and Cul3 with a 
4:4 stoichiometry could be generated. In this complex the structure of the POZ/BTB 
must be considered tetrameric and each subunit must interact with one molecule of 
Cul3. Interestingly, a α-helix of Cul3 docks into a cavity formed at the inter-subunit 
interface within the tetramer. The analysis of the model also shows that in this 
complex a larger portion of the POZ/BTB domain is involved at the complex interface 
if compared to the 1:1 model. Indeed, each POZ/BTB subunit interacts with two 
distinct Cul3 molecules. The interactions with the first Cul3 molecule are mediated, 
as described above, by A2 and B3 while with the second A1 is involved. We then 
considered the possibility to build up a larger aggregate by including other partners 
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for which structural information are available (Rbx1 and E2). By following the 
procedure reported in the methods section, a tetrameric RENKTCD11 POZ/BTB-Cul3-
Rbx1-E2 assembly was performed. This model clearly indicates that the C-terminal of 
RENKTCD11 POZ/BTB, to which the POZ portion of RENKTCD11 and the substrate are 
likely connected, is on the same side of the complex of E2 (figure 3.29). In other 
words the organization of this giant complex is compatible with the proposed 
functional role of RENKTCD11. Intriguingly, the tetrameric nature of RENKTCD11 
POZ/BTB makes, from the structural point of view, the traditionally complicated 
ubiquitin-protein ligases even more intricate. This consideration leads to the 
suggestive hypothesis that the ubiquitination process of specific substrates, which 
involves RENKTCD11 and other related proteins, requires assemblies endowed an 
even larger molecular complexity compared to 1:1 aggregates. 
 
 
 
Figure 3.27. Overall view of the interaction of a single subunit of the BTB/POZ
 KCTD11
 domain (in red) 
with Cul3 (in green). Residues which are missing in the sequence of the “short” form of REN
KTCD11
 are 
in grey. 
 
 
 
Figure 3.28. POZ/BTB/Cul3 interaction model with a 4:4 stoichiometry, POZ/BTB is reported in cyan, 
while Cul3 in red. 
63 
 
 
 
Figure 3.29. Model of complex between REN
KCTD11
 and ubiquitin-ligase E3. 
 
 
3.14 POZ/BTBKCTD11-Cul3 
 
Our data have been supplemented by Dr. Luigi Vitagliano (IBB, CNR of Naples) 
molecular modelling studies: the model based on the structure of the known complex 
Skp1/Cul1 (homologous RENKCTD11 and Cul3, respectively), each subunit of the 
tetramer of POZ/BTB interacts with Cul3 molecule, forming a complex of huge size 
with which interacting other fusion partners. This model was used to select the region 
of interaction between Cul3 and POZ/BTB. A peptide corresponding to residues 49-
68 (NH2-NSGLSFEELYRNAYTMVLHK-COOH) of Cul3 has been individuated as 
responsible of interaction with the domain POZ/BTB of RENKCTD11 (figure 3.30). Thus, 
in collaboration with Dr. Laura Zaccaro (IBB, CNR of Naples), the helix 49-68 of Cul3 
was synthesized by solid phase F-moc chemistry. The peptide synthesized was 
subjected to analysis by CD spectroscopy; the spectrum of peptide highlights a 
partially organization in alpha-helix (figure 3.31). The peptide 49-68 of Cul3 was used 
to perform ELISA assay with the Trx-POZ/BTB domain of RENKCTD11. The peptide 
binds POZ/BTB of RENKCTD11 with an affinity constant of 0.8 μM (figure 3.32). 
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Figure 3.30. Model of interaction of a single subunit of the BTB/POZ
KCTD11
 (cyan) with Cul3 (red). 
 
 
 
 
 
 
Figure 3.31. Far-UV CD spectrum of peptide 49-68 of Cul3 in 10 mM phosphate pH 7.5 buffer at 
25°C. 
NSGLSFEELYRNAYTMVLHK 
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Figure 3.32. Binding curve obtained from ELISA assay with Trx-POZ/BTB
KCTD11
 and 49-68 helix of 
Cul3. 
 
 
3.15 Heteronuclear single quantum correlation (HSQC) spectrum of 
POZ/BTB (+15 - +125) 
 
In order to conferm the interaction and to identify the aminoacid residues of POZ/BTB 
of RENKCTD11 involved in the binding with Cul3 has been conducted in collaboration 
with the prof. Carla Isernia (Dipartimento di Scienze Ambientali, Seconda Università 
di Napoli, Caserta,) a nuclear magnetic resonance analysis. POZ/BTB (+15 - +125) 
domain was expressed in minimal medium in presence of 15N (15NH4Cl) and purified 
as described in materials and methods. The final yield was been of 18 mg of labelled 
protein for litre of culture. The HSQC spectrum of POZ/BTB (+15 - +125) acquired at 
600 MHz and reported in figure 3.33 exhibits a large part of the expected 
resonances, which are well dispersed over a chemical shift range of approximately 
4.5 ppm in the proton dimension and 35 ppm in the nitrogen dimension. The high 
degree of dispersion in the spectrum is in accord with the presence of -strands, as 
this type of structure is typically associated with extensive dispersion. In contrast, the 
somewhat more crowded region in the centre of the spectrum is likely to contain 
resonances from helical regions which are typically associated with a more 
degenerate local environment leading to a lower degree of NMR resonance 
dispersion. Overall, the spectrum is consistent with a well-defined native structure 
with extensive tertiary interactions. When the peptide 49-68 of Cul3 is added to the 
protein solution all the signals in the 1H-15N HSQC experiments are reduced in 
intensity. At one-quarter equimolar peptide concentration, the intensity of the signals 
is sensitively reduced, thus suggesting an interaction between the protein and the 
peptide. This interaction is further confirmed by the STD experiment reported in 
figure 3.34. Moreover, for some residues a small chemical shift variation is observed, 
being probably the result of conformational changes in the fast exchange regime 
upon peptide binding. The chemical shift variation enhances upon titration of the 
protein with the peptide. These data clearly prove the interaction between the peptide 
49-68 of Cul3 and the domain POZ/BTB and allow to design a future accurate NMR 
analysis that will clarify the mechanism of interaction between the two molecules. 
66 
 
 
Figure 3.33. HSQC spectrum of POZ/BTB (+15 - 125). 
 
Figure 3.34. HSQC spectrum of POZ/BTB (+15 - +125) with helix 49-68 of Cul3 (ratio 1:8 protein-
peptide). 
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3.16 Interaction between KCTD5 and Cul3 peptide 
 
The helix 49-68 of Cul3 has been identified as region of interaction with the BTB/POZ 
domain, so we tried to investigate whether the same region of Cul3 was responsible 
for interaction with POZ/BTB domains of other KCTD proteins. It was chosen as the 
starting point KCTD5, a cytosolic protein that interacts with GRASP55, and whose 
crystal structure has been recently deposited (Dementieva I., et al. 2009). The 
POZ/BTB domain of KCTD5 with 5 aminoacids added at N-terminus (region 40-151) 
(figure 3.35) was cloned in expression vector pETM11 and expressed in E. coli. The 
domain BTB/POZ of KCTD5 was then purified to homogeneity and analyzed by light 
scattering. Light scattering results revealed a pentameric organization for BTB/POZ 
of KCTD5 in according with data present in literature. ELISA assay was performed to 
verify if the POZ/BTB of KCTD5 is able to bind the helix 49-68 of Cul3. The results 
obtained by ELISA show that POZ/BTB binds the helix 49-68 of Cul3 with an affinity 
similar to that of the BTB/POZ of RENKCTD11 (figure 3.36). Tests of co-crystallization 
of BTB/POZ of KCTD5 with the helix-Cul3 are in progress in order to identify either 
the region involved in the interaction of this domain either to obtain information useful 
for the characterization of the interaction of the BTB/POZ domain of RENKCTD11 with 
Cul3. 
 
 
 
Figure 3.35. Aminoacid sequence of the BTB/POZ domain of KCTD5. 
 
 
 
 
 
 
 
Figure 3.36. Binding curve obtained from ELISA assay with Trx-POZ/BTB of KCTD5 and 49-68 helix 
of Cul3. 
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4 DISCUSSION 
 
During the past few years, considerable progress has been made on the 
characterization of cullin-based ligases and on their possibility to target a very large 
number of substrates for ubiquitin-dependent degradation. Available evidences 
strongly suggest that POZ/BTB proteins function as substrate-specific adaptors of 
Cul3 ligases. The most of the POZ/BTB proteins contain an additional protein–protein 
interaction domain, however, several Cul3-interacting proteins appear to contain only 
a BTB domain, and are thus unlikely to possess the ability to interact simultaneously 
with potential substrates. The discovery that BTB proteins can assemble into a novel 
class of E3 ligases is of general importance, given the high number of POZ/BTB-
containing proteins present in the genome of different organisms. Some POZ/BTB 
proteins are characterized and are known to be involved in a variety of biological 
processes, including regulation of microtubules and microfilament dynamics, 
transcription, and apoptosis. Since POZ/BTB-containing proteins are mutated in 
some human diseases, re-investigating their function with regard to a possible role in 
ubiquitin-dependent degradation pathways may be rewarding. For this reason this 
work has been focused on the protein RENKCTD11. RENKCTD11 presents the domain 
POZ/BTB at N-terminus and its gene is deleted in many cases of medulloblastoma. 
In particular, RENKCTD11 inhibits cell growth by antagonizing Gli1-mediated 
transactivation of Hedgehog target genes via impairment of Gli1 nuclear transfer. The 
functional characteritation of RENKCTD11 variants with deleted domains has given 
preliminary data on the role played by the different domains of RENKCTD11 on control 
of medulloblastoma insurgence. These investigations have demonstrated that the 
mutant of RENKCTD11 with the deleted POZ/BTB domain is inactive. Although these 
data indicate that the POZ/BTB domain is fundamental for RENKCTD11 function, the 
specific biological role of this domain is still unknown. In this PhD thesis we describe, 
firstly, a novel protein form of RENKCTD11, with a new translational start point placed at 
39 aminoacid residues upstream of the +1 methionine previously identified (Gallo R., 
et al. 2002). We have individuated exact extension of POZ/BTB domain located at 
the N-terminus, containing residues +15 - +116.  POZ/BTB of RENKTCD11 shows 
analogies with the T1 domain of Kv4, that mediates homo-tetramerization in 
numerous crystal structures and so we have verified the oligomeric state of 
RENKCTD11. Our data demonstrate that RENKCTD11 is a tetrameric protein and that its 
POZ/BTB domain is responsible of tetramerization. In vitro experimental analyses 
have indicated that RENKTCD11 interacts with the protein Cul3. This suggests that the 
protein may be involved in the complex of the ubiquitin-protein ligases. All structures 
of reported POZ/BTB-Cul3 complexes contain a single POZ/BTB domain interaction 
with a single Cul3 molecule. A convincing complex between POZ/BTB of RENKCTD11 
and Cul3 with a 4:4 stoichiometry could be generated considering the structure of the 
POZ/BTB as tetramer and the interactions of each subunit with Cul3. In particular the 
helix corresponding to residues 49-68 of Cul3 has been individuated as responsible 
of interaction with the domain POZ/BTB of RENKCTD11. NMR analyses and 
immunological assays have confirmed this data. Few informations were obtained on 
the C-terminal region of RENKCTD11, but it is possible to assume that in this portion 
not only it is present a motif involved in protein–protein interaction but also post-
translational modifications that could explain the difficulties came across during the 
heterologous expression in E. coli. In fact, it is reported in literature that in addition to 
POZ/BTB domain, the adaptors contain a second protein–protein interaction motif 
that binds the targeted substrate [Petroski M.D., et al. 2005]. Our findings unveil a 
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possible mechanism of regulation of the Hedgehog signalling, in which RENKCTD11 is 
a critical mediator of Gli1 function. In this mechanism RENKCTD11 regulates indirectly 
Gli1. In fact, RENKCTD11 binds, probably with its POZ/BTB, Cul3 and in the same time 
with its C-terminal the effective regulator of Gli1. The results of these interactions are 
the ubiquitination and the proteasomal degradation of Gli1 regulator. The consequent 
impairment of Gli1 function results in the inhibition of cell growth. These data provide 
a novel mechanism of regulation of Gli1 transcriptional activation, which may have 
important implication in tumour developmental and biology and further emphasize the 
design of new class of therapeutic agents to use for treatment of medulloblastoma. 
KCTD proteins contain a N-terminus POZ/BTB domains and variable C-terminal with 
biological function unclear yet. KCTD5 has been the first member of the family KCTD 
to be characterized so far [Bayon Y., et al. 2008]. Recent studies demonstrate that 
KCTD5 interacts specifically with Cul3, and forms oligomers through its POZ/BTB 
domain [Dementieva I. S., et al., 2009]. Our results show that POZ/BTB of KCTD5 
binds the helix 49-68 of Cul3 with an affinity similar to that of the BTB/POZ of 
RENKCTD11. These findings confirm that KCTD5 is a substrate-specific adaptor for 
Cul3-based E3 ligases and that other members of KCTD family can be involved in 
similar mechanism of regulation. The tumour development is often connected with 
alterations of these mechanisms of regulation that according to dysfunction is 
necessary to have on or off. So, the characterization of the regions of interaction 
constitutes the base to design molecules with agonist/antagonist function to use for 
therapy. Our studies not only represent a crucial step to understand the molecular 
mechanism of RENKCTD11 but also lay the foundations to develop molecules of 
pharmaceutical interest for the therapy of disease in which proteins belonging to the 
KCTD family are involved. 
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